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Abstract
The development of sequencing technology has had a rapid pace during the last
years and today, the sequencing instruments harbors enormous capacity. This the-
sis is about the development of methods to make the most out of this capacity and
to use it for various applications.
In paper I, a dual tagging system for sequencing large sample sets was devel-
oped. To proof the concept, 4,700 dogs were subjected to amplicon sequencing of
the 2nd exon of the gene DLA-DRB1 using a 454 genome sequencer. By using
a combination of two tags, 4,992 samples can be analyzed within the same run
using only 148 tagging sequences. In our experiment, 95% of the generated PCR-
products achieved a sufficient read depth (≥ 20×) for variant calling.
Paper II solved a problem coupled to amplicon sequencing experiments, namely
contamination of sequence data from unwanted by-product formation. By hy-
bridizing an oligo nucleotide coupled to a fluorescent dye to the wanted PCR prod-
ucts, fluorescence activated cell sorting (FACS) could be used to enrich the target
molecules after emulsion PCR. The resulted in a nearly three-fold increase of qual-
ity reads from a sorted library compared to a non-sorted.
Since the cost of sequence data has decreased during the last years, the budget item
of library preparation have became more abundant in sequencing experiments. In
paper III, library preparation using cheap bulk enzymes was explored regarding
various factors affecting process efficiency. Multiplex sequence capture was also
evaluated for processing up to eight samples at the cost of one single reaction.
Using circulating tumor DNA for measuring systemic tumor load have been pro-
posed and investigated by several studies. In paper IV, the utility of exome
sequencing for this application was assessed. The findings suggests that the ability
of detecting low-frequent alleles is insufficient for clinical use where detection levels
of < 0.5% is required.
Keywords: massive parallel sequencing, cancer genomes, prostate cancer, biomark-
ers, library preparation, amplicon sequencing, DNA barcodes, circulating DNA,
enrichment, targeted sequencing, exome sequencing.
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Preface
Developing methods for DNA research is like climbing. There is a branch
within climbing called bouldering. Here, the goal is to complete a short route
at a low height without the use of ropes. Since the climb is condensed, it con-
sists of only a handful of moves, each of which is carefully defined. Therefore,
within bouldering one talks about solving problems rather than completing
routes. In harder boulder problems, there are often specific moves that are
extra difficult and requires several rounds of trial and error to be conquered.
First when the climber is capable of performing each discrete move with per-
fection, the problem can be completed in one sequence. The same applies
when developing a laboratory procedure for solving a technical puzzle. Each
step has to be carefully designed and optimized and to do this, several rounds
of iteration have to be undertaken. First when every step can be performed
with perfection, the protocol as a whole is ready to be applied in a biological
study. Welcome to my thesis.
The field of DNA research is moving at an incredible speed and during the
process of writing this book, several new findings were published and the
text had actually to be rewritten. These are exciting times. Welcome to my
thesis, dear reader.
Mårten Neiman
Stockholm, April 29, 2013
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Scope
The papers of this thesis are about making the most out of DNA sequenc-
ing experiments and to investigate their limitations with the objective of
answering biological questions. The thesis is divided into three chapters.
The first chapter is mainly about the biological matters that need to be
considered when developing these kinds of methods. Understanding the un-
derlying biology and the way of designing studies of such is necessary for
identifying technological limitations and how to circumvent these.
The second chapter is about the technology of DNA sequencing. The purpose
of this chapter is not to give a comprehensive description of all methods
available but to discuss technologies more or less associated with the papers.
Since there is much to learn from history, a historical perspective of the
technical developments is also undertaken.
In the third chapter, the research behind the papers and its value to the
scientific community is discussed, trying not to repeat the content of the
actual papers. This book is written for a reader that is a researcher within
the field of DNA sciences or other related research areas.
xiii
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Chapter 1
Introduction
1.1 DNA, genes and environment
DNA has fascinated humans for decades. It was observed for the first time
in 1869 [1], shown to carry the genetic information in 1944 [2] and its char-
acteristic double helix structure was resolved in 1953 [3]. The abbreviation
DNA stands for deoxyribonucleic acid; deoxyribose is the sugar unit that,
together with phosphate, builds up the backbone, and nucleus means core
and this is where it is found in eukaryotic cells. The DNA molecule is a poly-
mer consisting of four subunits called nucleotides and as the letters of this
text form words, the sequential order of these four nucleotides determines the
genetic content. A nucleotide can be subdivided into three units: a sugar, a
phosphate group and an organic base. All four nucleotides share the identical
sugar unit and phosphate group but have different bases: adenine (A), gua-
nine (G), cytosine (C) and thymine (T). The double helix structure consists
of two DNA molecules twisted around each other, that are held together by
hydrogen bonds between the base units of the nucleotides. A certain base can
only bind to another certain base forming a base pair so that the two DNA
molecules complement each other. The base A binds only to T, whereas C
only to G and vice versa. One of the main features of DNA is its ability to
be copied. This is carried out by an enzyme called DNA polymerase which
uses this principle of base pairing to make a complementary strand from a
single stranded DNA molecule.
The complete genetic content of an organism is called genome and different
parts of a genome have different functions. One such function, and perhaps
1
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the most thoroughly investigated, is the coding for proteins. In eucaryotic
cells, the complete coding DNA sequence needed to create a protein is not
continuously ordered, but split up into smaller coding pieces called exons,
which are separated by noncoding pieces called introns and flanked by reg-
ulatory elements creating a wholeness called a gene. In order for a cell to
make use of a gene, by producing its corresponding protein, the genetic infor-
mation must first be boiled down into a single continuously coding sequence
and transported to the protein producing ribosomes. This is carried out by
the cell through a process called transcription where the genetic information
is copied and spliced into a molecule called messenger RNA (mRNA), that
is further processed into an amino acid chain through a process called trans-
lation. In addition to transcription, the genetic content of a cell can also be
copied in the eve of a cell division and this process is refered to as replication.
This whole concept of a unidirectional informational flow, DNA->DNA,
DNA->RNA and RNA->protein, is called the central dogma of molecular
biology and was first formulated by Francis Crick in 1958. At this time, the
understanding of cell mechanisms was still in its early days so what Crick
stated then was basically:
"Once (sequential) information has passed into protein it cannot
get out again."
Since he wasn’t sure whether the transfers RNA->RNA, RNA->DNA or
DNA->protein existed he avoided to mention these but when the knowledge
grew he was criticized for simplifying things so in 1970 he reformulated the
dogma and argued that what he stated in 1958 was still valid [4].
The human genome consists of 3,137,161,264 letters (hg19) [5], or bases.
If one should spell out the whole sequence using a character width of 1 mm,
the human genome would span 3,137 km which is the same distance as trav-
eling from Stockholm to Paris and back agin. In this scale, an average gene
would span 27 m, the protein coding part of a gene would be 1.3 m and a new
gene would occur every 300 m [6]. Like the genomes of nearly all mammals,
the human genome is a so called diploid genome meaning that each somatic
cell possesses two copies: one inherited from the mother and one from the
father.
1.1. DNA, GENES AND ENVIRONMENT 3
In February 2001, two competitive research groups simultaneously published
the first draft sequence of the human genome [6, 7] revealing an unexpected
low proportion of the genome being protein coding, 1.1% and 1.4% respec-
tively. What the rest 98.6-98.1% of the genome is doing has been a subject
for discussions but the fact that genes and genomes contain regulatory ele-
ments has been known since the 1950s [8, 9]. The hypothesis of junk DNA
was introduced in 1972 by the Japanese-Korean-American geneticist Susumu
Ohno [10] who, based on the weight of human and bacterial genomes, argued
that a human genome cannot contain genes in a proportional amount to its
size (weight) since it had been showed that a gene locus has a probability
of 10−5 per generation to achieve a deleterious mutation and if the number
of genes becomes greater than or equal to 105, the overall probability be-
comes greater than or equal to 1 which did not seem reasonable. This line of
thoughts resulted in two conclusions: firstly, there must be an upper limit of
how many genes a genome can harbor and secondly, the vast majority of our
genome functions as a buffer for the cell to make mistakes during replication
without harming its genes; the function of doing nothing.
The Encyclopedia of DNA Elements (ENCODE) project was initiated in
2004 in order to characterize all functional elements of the newly completed
human genome [11,12]. In September 2012, 30 articles related to the project
were published in high-impact journals like Nature, Genome Research, and
Genome Biology. The massive project had found that 80.4% of the genome
participates in at least one biochemical event, identified 20,687 protein cod-
ing genes (1.22% of the genome) and an estimate of 60-80% of the genome
was shown present in at least one transcript in at least one cell type [13]. The
function of all this transcribed but non-coding DNA is either being part of
the translation machinery (e.g. rRNA, tRNA), RNA processing machinery
(e.g. snRNA, snoRNA) or as different regulatory RNA species (e.g. miRNA,
siRNA, lncRNA). Noticeably, the vast majority of our genome is functional
in some way and the hypothesis of junk DNA must be regarded as disproved.
Accordingly, the main function of the genome is not only coding for proteins
but also to facilitate a machinery for the cell to respond to the environment
and produce desired proteins in proper amounts. In other words, to regulate
gene expression. It then follows that the characteristics of an organism is not
only a product of its genes but also a result of the environment it lives in.
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Consider two pines: one grows in a deep wood and the other in a crack of
on a windblown rock close to the sea. These two trees do not shear the same
appearance at all. They do share the same genome but in order to survive in
their respective environment, the trees have adapted themselves. Different
traits are more or less influenced from genes or environment. For example,
if an organism is struck by the lightning and injured, its genes does not have
any influence in this (unless it is a giraffe) but the injure is a pure effect
of the environment. The sex, on the other hand, is completely determined
by the genes in (almost) all mammals. But most traits need both genetic
and environmental factors to occur. For example obesity, which prevalence
is not only affected by life style factors, such as lack of physical exercise or
abundance of food but there is also an inheritable genetic component [14].
1.2 Genetic variation
The ability to vary genetic content is the mechanism enabling the never
ending iterative process called evolution. The offspring of organisms is not
genetically identical to its ancestors and some of its abilities might be sophis-
ticated, extended or lost. The environment decides if the offspring’s genetic
set-up was beneficial or not. If abilities like feeding, escaping predators or
breeding were improved, these variants are likely to be incorporated in the
growing population whiles harmful variants are less likely to survive.
When a cell divides, the genome is replicated. The replication machinery
is not perfect and errors occur during this process. If the new cell is a germ
cell, these errors will be passed on to all cells of the offspring and through
this, genetic variation is introduced. In 2007, the project 1000 genomes was
initiated with the aim of making a comprehensive map of genetic variation
in humans. In the pilot phase of the project, two trios of mother-father-child
were sequenced at high coverage using multiple platforms in order to estimate
the germline single nucleotide mutation rate. After confirmative resequenc-
ing experiments they found 35 and 49 germline mutations respectively, which
yielded an estimated mutation rate of 10−8 per generation and base pair [15].
The word mutation comes from the latin word mutatio which means change
and the most abundant type of genetic variation is point mutations followed
by short insertions and deletions (indels) and structural variation. When
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studying individual genomes it is preferable to compare them to a refer-
ence genome, which represents a consensus of the most common variants
of all positions, and look at the deviations from this. The term SNP (sin-
gle nucleotide polymorphism, pronounced snip) was first defined as common
nucleotide substitutions with a minor allele frequency (MAF) of ≥ 5% but
nowadays, one also talks about rare SNPs and the term could basically be
interpreted as singe nucleotide variation (SNV) of any frequency.
If the genome of a randomly chosen (healthy) individual was compared to the
reference sequence one would find around 3×106 SNV’s out of which far from
all are expected to be functional. To clearify the picture, the regional posi-
tions of the SNV’s can be used to estimate their functional impact. When
comparing genomes from different species, some regions (not only within
genes but also intergenic) are said to be conserved, which means that they
are highly similar even between distantly related organisms and since they
have been kept intact throughout evolution they are thought to be func-
tionally important. To estimate the fraction of functional variants, the 1000
genomes project investigated how many SNV’s were situated at conserved
positions. To further evaluate the SNV’s damaging potential they looked in
The Human Gene Mutation Database [16] and at how common the SNP’s
were (common variants are expected to be less harmful because of evolution-
ary pressure). A SNV’s prevalence can be subdivided in common variants
(> 5%), low-frequent variants (0.5− 5%) and rare variants (≤ 0.5%). Strik-
ingly, it was shown that healthy individuals carry 2-5 potentially damaging
rare variants and 1-2 rare variants previously associated with some form of
cancer (see table 1.1) [17].
Variant type Common Rare
Non-synonymous 2,500 130-400
Damaging 20-40 2-5
Loss-of-function 150 10-20
Cancer associated - 1-2
Table 1.1 Expected single nucleotide variants in conserved re-
gions for a randomly selected healthy individual estimated by the
1000 genomes project.
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So, how can people still remain healthy? There are two copies of each gene
meaning that there is a backup copy. Also, several genes can have similar
functions, so called genetic redundancy. However as mentioned earlier, not
only our genes determine our health but also our environment, life-style and
stochastic factors (also known as luck).
1.3 Studying genes and traits
Since long before the genetic information carrying role of DNA was discov-
ered, efforts have been made to associate inherited genetic variants with
physiological features. The earliest associations were made long before any
technology for genotyping was available and instead, so called linkage analysis
was used. Linkage is the phenomenon of genetic components being inherited
together because of their physical nearness. Among the first observations
were the sex-linked traits of red-green color blindness and haemophilia [18].
There are different genetic mechanisms behind different traits and a com-
mon way of categorizing is by subdividing them into single gene causing
(mendelian) traits and complex traits involving several genes. Completely
mendelian phenotypic traits are rare but some examples are dry earwax (first
visible trait associated with a SNP) [19] and a form of albinism [20]. A lot
of traits have been thought to be mendelian but have later been shown to be
complex. An example is eye color were the gene OCA2 accounts for 74% of
human eye color variation [21].
Finding the gene behind a mendelian trait is easier than trying to under-
stand the complete mechanism behind a complex trait, as one single gene
has a much larger effect size than each of the components of a complex trait.
Effect size is the amount of impact contributed by a gene on a trait. The
smaller the effect size, the larger sample size is needed to gain sufficient sta-
tistical power to detect it (see figure 1.1).
The size of the human genome, its many polymorphic positions it contains
and the fact that it is very expensive to analyze the whole genome in thou-
sands of samples makes it challenging to associate genetic variants and traits.
Since investigating the whole genome is unfeasible, the search has to be re-
stricted to selected parts rising the question: where to look? Currently,
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Figure 1.1 Correlation between sample size and the smallest
detectable effect size at a power of 0.8 and a significance level of
5× 10−8 given equal amounts of cases and non-cases.
there are two approaches for answering this question. Firstly, genome-wide
features like SNP’s or coding regions can be targeted. This is the more gen-
eral approach since it does not require any previous knowledge about the
biological functions behind the trait to be studied but it is restricted to pre-
viously known SNP’s or genetic elements of similar function. Secondly, genes
previously associated with the trait of interest, or genes having a biochem-
ical function possibly related to the trait can be pinpointed. This second
approach, commonly referred to as fine mapping, requires more knowledge
in order to select interesting regions but allows for finding rare variants and
investigating many types of distinct regions. Nevertheless, a genome-wide
study could be followed by a fine mapping study to refine the first’s findings.
The outcome from a genetic association is an estimate of the relative proba-
bility that a person with a certain gene variant develops a certain physiolog-
ical feature, like a disease, compared to a person without the variant. This
information could be used to identify individuals with high risk and change
their life style accordingly and perhaps doing health checkups more often.
The information can also be of use in screening programs where persons at
high risk can be screened more often than people in general and if protecting
8 CHAPTER 1. INTRODUCTION
markers are known, these low-risk individuals can be assessed more seldom.
Another important use is when the dose of medical drugs is determined since
both the rate of degradation and the degree of side effects are associated with
genetic variants [22–24].
During the first years of the new millennium, high density SNP arrays entered
the market making genome wide SNP scans possible [25–27]. The earliest
versions were able to detect allelic imbalances in 600 positions [25] and since
then, the density of the arrays have grown and today (early 2013), Illumina
offers a chip capable of analyzing up to 4.8 million features, corresponding to
one marker per 680 bases throughout the genome, in four samples simultane-
ously [28]. These platforms have been the basis of genome-wide association
studies (GWAS) where often thousands of individuals are genotyped in mil-
lions of genetic loci.
Because of the fact that only previously known SNP’s, common and low-
frequent, are included in a GWAS (since they have to be known when the
SNP-chip is designed) and that these levels of occurrence are seldom alone
coupled to disease states, highly penetrant variants are rarely found (see
figure 1.2). This is a consequence of the common disease/common variant
(CD/CV) hypothesis discussed by David Reich and Erik Lander in 2001 [36].
It states that common diseases are caused by common variants and their
logical reasoning is that the effect size of each common variant for a common
disease must be small relative to those of rare disorders.
Because of the very high number of markers that are tested for association in
a GWAS, some precautions regarding significance level must be taken. Tradi-
tionally, a significance level of alpha = 0.05 is regarded as sufficient, meaning
that the null hypothesis of no correlation is rejected if the p-value is less
than 0.05. This means that in 5% of the tests, the null hypothesis is rejected
even though it is true. In a GWAS where one million SNP’s are tested, each
with a 5% probability of its null hypothesis being falsely rejected, the false
discovery rate would be inadvisable high. One way of handling this is by
requiring a higher significance level. When choosing an appropriate level for
a specific study, factors like number of included SNP’s and the distribution
of linkage disequilibrium within the studied population are to be considered.
As an example, the genome-wide two-sided significance threshold for an Eu-
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Figure 1.2 The effect size of associated genes in relation to the
allele frequency in control samples [29–34]. A major proprtion of
genetic findings tend to lie between the dashed lines [35].
ropean Caucasian population has been estimated to 7.2× 10−8 [37].
Another computational challenge in a GWAS is performing multi-locus anal-
ysis, that is analyzing interaction effects between SNP’s. Testing pair-wise
interaction among one million SNP’s demands a lot of computational power
so some kind of filtering is preferred. A common strategy is to first per-
form a single-locus analysis and then move on into multi-locus analysis using
the most significant findings. However using this strategy, there is a risk of
missing significant interaction between SNP’s that does not influence risk of
disease alone [35].
The GWAS strategy have been successful, enabling the association of thou-
sands of genes and traits. As of April 25, 2013, there was 1,577 publications
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and 9,914 SNPs in the Catalog of Published Genome-Wide Association Stud-
ies supplied by The National Human Genome Research Institute [38].
1.4 Cancer genomes
Cancer is a genetically driven disease. It occurs through cumulative somatic
mutations in tissues. The word somatic is derived from Greek and means of
the body. Somatic mutations occur after conception, meaning that they are
not shared between all cells of a body but only within a subpopulation of
cells that have a common ancestor where the mutation occurred. In contrast,
germline variation occurs at meiosis and is inherited to the offspring which
carries the variation in all of its cells. If the variation is not damaging in
a way that makes mating non-feasible, it can be incorporated to a growing
population (discussed in chapter 1.2).
Cancer occurs when the accumulated somatic mutations of a cell causes an
increased division rate and over time, a tumor is grown. These mutations
occur when cells divide in our self repairing and renewing bodies because of
limitations of our DNA replicating machinery. The number of cell divisions
that takes place in the human body during a normal life time has been es-
timated to 1016 [39], which gives a high probability of some cell collecting
sufficient advantageous mutations for developing a tumor. Mutations can
also occur from the external exposure of DNA damaging agents, such as ion-
izing radiation, ultra violet (UV) radiation, tobacco smoke and chemicals.
The number of mutations carried by a cancer tumor varies between different
types. It has been estimated that a typical solid tumor (such as one derived
from the colon, breast or pancreas) has 33 to 66 genes mutated so that their
coded amino acid sequence is altered (non-synonymous mutations) [40]. Tu-
mors located in tissues more exposed to DNA damaging agents, such as skin
and lung tissue, are also more extensively mutated. For example, a lung can-
cer tumor in a smoking patient harbors ten times as many mutations as the
tumor of a non-smoking patient [41]. The number of somatic mutations in
the cells of the body are accumulated over time and luckily, it takes a while
for a cancer cell to evolve. This is why the risk of cancer increases with age.
Naturally, not all accumulated somatic mutations of a tumor are causative.
When studying somatic variation in cancer, it is common to categorize them
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into driver mutations, mutations that contributes to the cause, and passen-
ger mutations, mutations also carried by the tumor but without affecting
its properties. A lot of effort has been made to map and understand which
genes are critical for tumor development and so far, approximately 140 genes
have been identified as driver genes, which means that they can drive tu-
morigenesis if they are mutated. These 140 genes are involved in three main
functions of the cell: genome maintenance, cell survival and cell fate and an
average tumor has two to eight of these genes mutated [40]. Cancer driver
genes are classified as proto-oncogenes or tumor suppressor genes. If a proto-
oncogene is genetically altered, it can be activated into an oncogene. The
activation makes the gene over expressed or hyperactive in some way, ei-
ther by chromosomal rearrangements, where the proto-oncogene is combined
with a more active transcription start site and/or enhancer elements, by
point mutations in regulatory/coding elements making the protein product
more abundant/active or through gene amplification [42]. The proteins of
oncogenes are often part of the proliferation control machinery or apoptosis
regulation and are the targets of several cancer therapies.
The analysis of cancer genomes may have two aims: studying one patient
or studying the disease. The goal of investigating the cancer genome of one
patient could be to characterize tumor specific genetic alterations in order
to tailor therapy and/or biomarkers. To do this, DNA from tumor tissue
is investigated and compared to germline (normal) DNA, often derived from
blood, so that only somatic tumor specific variation is considered in the anal-
ysis. In order to study the disease, a cohort of patients needs to be investi-
gated, often as tumor-normal pairs, with the goal of identifying biomarkers,
characterize clinically relevant subtypes, identify therapeutic drug targets or
to simply achieve a deeper understanding of the disease mechanisms [43].
1.5 Biomarkers
According to the National Cancer Institute (NCI) Dictionary of Cancer
Terms [44], the definition of a biomarker reads as:
"A biological molecule found in blood, other body fluids, or tissues
that is a sign of a normal or abnormal process, or of a condition
or disease. ..."
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Figure 1.3 Number of hits per year in PubMed from the search
string: "cancer biomarker".
This molecule might be a protein, DNA, RNA or a small metabolic product.
Today, several biomarkers for various forms of cancer have been characterized
[45]. Generally, a biomarker can provide several sorts of information:
• Risk - a marker can tell if a patient has an increased (or decreased)
risk of developing disease. This is often a genetic variant but can also
be a physiological trait like mammographic density [46].
• Diagnosis - the marker tells if the patient suffers from disease or not.
A blood based marker has the potential of detecting a tumor before it
becomes palpable.
• Prognosis - disease is a fact but how aggressive is it? Continuously
measurements of a biomarker could monitor tumor burden, therapy
response and prevent over-treatment.
• Relapse - when the patient is cured a biomarker could tell if the disease
returns.
As shown in figure 1.3, the number of publications with the keyword "cancer
biomarker" has grown for each year and in 2011, more than 40 new papers
were published per day. But only a handful of these (less than 3 per year
between 1994-2003 [45]) are approved by The US Food and Drug Administra-
tion and implemented into clinical practice. There are two main categories of
biomarkers that fails to reach the clinic: firstly, those that are true discover-
ies but with poor performance so that their contribution of information is of
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Figure 1.4 Cumulative probability of developing breast or
prostate cancer before a certain age among Swedish women and
men respectively showing that the risk of prostate cancer comes
later in life. Data from [49].
limited clinical use and secondly, those that are false discoveries (even thou
they are statistically significant findings). To aid the assessment of quality
of a tumor marker study, guidelines for providing relevant information and
using appropriate scientific methods have been proposed [47]. The goal of
this was to promote complete reporting and make it easier for other scien-
tist to understand the context of the results. The largest hurdle for new
biomarkers to reach the market is that, for being worth the investment to
take them into the clinic, they have to perform significantly better regarding
sensitivity and specificity than existing biomarkers. This means that they
have to provide such vital information that decisions of therapy can be made
more accurately and so that the clinical cost of doing the actual test can be
motivated by savings in over/under treatment [48].
1.6 Prostate cancer
In Sweden, prostate cancer is the most common form of cancer followed by
breast cancer. In 2011, 9,663 patients were diagnosed with prostate cancer
which corresponds to 34.2% of all cancer cases in men [49]. The relative 5-
year survival was 87.3% and 10-year survival was 68.5%. The disease occurs
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Figure 1.5 The yearly incidence and mortality of prostate can-
cer in Sweden per 100,000 person-years standardized to the World
Standard Population. Data from NORDCAN [51].
relatively late in life, even for being a cancer and compared to breast cancer,
the cumulative risk of being sick before a certain age becomes notable about
ten years later than in breast cancer (see figure 1.4). Only 85 cases where
the patient’s age at diagnosis was ≤ 50 years were reported during 2011 in
Sweden and the mean age at diagnosis is 72-74 years [50]. The annual inci-
dence of prostate cancer in Sweden has doubled since the 1970’s from a little
less than 50 cases per 100,000 person-years to around 100 cases per 100,000
person-years (age standardized to the World Standard Population) and about
2.1% increase per year over the last 20 years (see figure 1.5) [49, 51]. This
increase is much due to the introduction of the PSA test (discussed later in
this chapter) in the 1990’s but during the last five years, the incidence of
prostate cancer has somewhat stabilized whiles the mortality has remained
relatively unchanged since the 1960’s [49].
The most established risk factors for having prostate cancer are ethnic
origin, age, family history and high concentrations of insulin growth factor
I (IGF-I) in blood. The three former factors cannot be affected through
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Figure 1.6 The relative risk of various life-style and dietary fac-
tors investigated for lethal prostate cancer. Since these esti-
mates comes from different studies with different design and defi-
nitions of outcome, between variable comparisons should be done
with caution. Data obtained from [52].
life-style, while the latter is thought to be affected by fat consumption since
a raised insulin production also results in higher IGF-I levels [50]. Several
life-style and dietary factors have been investigated for affecting the risk
of having prostate cancer but so far, mostly conflicting or negative correla-
tions have been observed. Fat intake has been shown to have a minor effect
(OR: 1.4, 95%CI: 1.1-1.8) [53] as well as calcium (RR: 1.34, 95%CI: 1.04-
1.71) [54]. Nevertheless, if the outcome is defined as lethal prostate cancer
instead, several factors have been shown to have an effect. This could be
because they have influence on the effectiveness of therapy or that several
biological pathways are activated in the progression to lethal disease and
hence, more opportunities for interaction [52]. In figure 1.6, the effect from
some environmental factors on the risk of having lethal prostate cancer have
been plotted.
As mentioned, family history is an established risk factor for prostate can-
cer. Having a first-degree relative diagnosed with prostate cancer means a
doubled risk (RR: 2.5, 95%CI: 2.2-2.8) and having two first-degree relatives,
the risk is almost fourfold (RR: 3.5 95%CI: 2.6?4.8) as estimated through a
meta-analysis done in 2003 [55]. As seen, the risk is affected by the number
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of affected relatives but it is also affected by the age at diagnostics of the
affected relative [56]. These strict correlations suggests a high heritability of
prostate cancer and a twin study has estimated that more than 40% of its sus-
ceptibility is due to genetic factors [57]. In spite of this, no highly penetrant
genes have been identified and the inheritance pattern of prostate cancer
has been found to be more genetically complex. Several GWAS have suc-
cessfully attempted to find association between common SNP’s and prostate
cancer incidence and until recent, almost 50 loci had been identified with
low to moderate effect (OR between 0.83-1.79) [58]. In April 2013, a large
international consortium called PRACTICAL presented their findings from
genotyping approximately 25,000 cases and controls using a custom array
(iCOGS). They had found 23 new loci associated with prostate cancer and
more than 70 loci in total [59]. One of the most penetrant loci found so
far is a rare (MAF: 0.1% in the U.S.) single nucleotide variant located in
the gene HOXB13 identified by exon sequencing of 202 susceptibility genes
in an american study (OR: 9.5, 95%CI: 3.5-803.3) [60]. This findings have
been verified by a Swedish study (OR: 3.5, 95%CI: 2.4-5.2) [30] and another
american study (OR: 4.42, 95%CI: 2.56-7.64) [61].
Prostate cancer is more or less symptomless at an early stage since the tu-
mor is often located in the peripheral zone of the prostate [62]. The prostate
gland is located just below the urinary bladder and surrounds the urethra.
In a healthy person, the prostate has the size of a walnut and a mass of 11
g [63]. It functions as a secretor of slightly alkaline fluid that is a major part
(50-75% of volume) of semen [64]. Because of the inaccessible placement of
the prostate, a tumor is not palpable in the same degree as for example a
breast tumor. At a later stage, large tumors can affect the urethra making
urination difficult for the patient. However, this symptom is also coupled to
benign prostatic hyperplasia, a very common, non-malignant disorder among
older men [65]. It is not uncommon that a person lives his life with prostate
cancer without clinical symptoms and eventually dies from other causes. In
a recent study, the prostates of 340 deceased trauma patients were examined
(age 1-81 years) and 41 prostate cancer cases were found. The prevalences
observed for each age strata were ≤ 39 years: 0.7%, 40-49 years: 0%, 50-59
years: 23.4%, 60-69 years: 34.7% and 70-81 years: 45.5% [66]. When severe
symptoms of prostate cancer occurs, it is often at a late stage of aggressive
disease when bone metastasis causes pain.
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Because of the lack of symptoms at an early stage, the need for biomark-
ers or early imaging of prostate cancer is imminent [67, 68]. One of the
most famous markers for prostate cancer is a protein called prostate specific
antigen (PSA) and its prognostic value was established for the first time in
1985 [69]. PSA is a major protein in semen and is produced by secretory
epithelial cells of the prostate. The expression of PSA is positively regulated
by the androgen receptor meaning that it is responsive to steroid hormone
levels [70]. However, a raised PSA-level does not necessary have to be due
to a tumor but is also associated with benign prostatic hyperplasia [68, 71].
This means that a large proportion of those without prostate cancer can still
have high PSA levels.
There are PSA-based screening programs for enhancing detection of prostate
cancer at an early stage. There has been (and still is) a massive debate on
the use of these programs since the specificity of PSA is rather low, causing
healthy persons being needlessly investigated for prostate cancer and over
diagnosis of non-lethal cancer [72, 73]. According to an estimation of the
benefit from the PSA screening between 1986-2005 in the U.S., more then 20
persons had to be diagnosed with prostate cancer for every man who actu-
ally benefitted from it [73]. Additionally, a randomized trial study conducted
in Sweden concluded that for preventing one prostate cancer related death,
293 men needs to be invited for screening out of which 12 have to be diag-
nosed [74]. Nevertheless, an European randomized study, including 162,388
participants, showed a 20% mortality reduction in the screening group dur-
ing 9 years of follow-up [67]. Also, as a diagnostic test and as a marker for
disease progression, PSA has proved to be very useful.
Initially, when a patient is investigated for prostate cancer, a PSA-test is
taken, the prostate is examined by a physician through rectum and some-
times, an ultrasound examination is done. If the suspicion remains after
these proceedings, biopsies of the prostate are taken and examined by a
pathologists who assigns a so called Gleason Score based on the microscopi-
cal evaluation of the prostate glands [62,75].
Tumors restricted to the prostate gland, so called localized disease, are di-
vided into three risk groups of high, medium and low risk based on PSA-value,
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tumor size and Gleason Score [76, 77]. Patients that have localized prostate
cancer are treated with radiotherapy, radical surgery or active surveillance
depending on risk group, age and general condition. Tumors spread to ad-
jacent tissue or metastasized to other organs, such as lymph nodes or bone,
are primary treated with hormonal therapy [78].
1.7 Circulating tumor DNA
It has been known for decades that cancer tumors release cells in the blood
stream that are transported to other organs and seeding new tumors, so
called metastasis. This occurs at a relatively late stage of the disease but the
tumor leaves molecular traces in the blood also at earlier stages. In general,
tumor cells are more biochemically active than normal cells and as a conse-
quence, they also release a larger quantity of matter to their surroundings.
This might be DNA, RNA, proteins and small metabolic molecules and if
they can be distinguished from molecules released from normal cells or are
present in abnormal quantities, they might provide information regarding
tumor characteristics. While proteins and metabolic molecules are mainly
investigated in a quantitative manner, nucleic acids can carry tumor specific
features within the molecule that can be confidently detected using modern
technology.
The presence of free circulating nucleic acids in blood has been known since
1948 [79] and they are thought to originate from macrophages releasing DNA
after engulfing cellular debris from necrotic cells [80,81]. But it was not until
1994 that its importance as a diagnostic and prognostic cancer marker was
revealed when tumor specific mutations in the oncogenes KRAS and NRAS
were detected for the first time [82, 83]. It had already been observed that
the total concentration of circulating DNA in blood from cancer patients
were significant higher than in healthy donors, but the variation within the
groups was large [84]. The concentration range of circulating DNA in blood
have been estimated to 0-100 ng/ml among healthy individuals with a mean
of 30 ng/ml and between 0 and >1000 ng/ml among cancer patients with
a mean of 180 ng/ml [85]. The findings from studies attempted to inves-
tigate the amount of DNA in blood have been very inconsequent and this
uniformity is thought to be related to the different methods used for DNA
quantification, but even a large prospective study observed untenable large
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variation proposing that it was due to variation in sample treatment and/or
variation between the populations studied (participants recruited from all
over Europe) [86].
However, it has also been shown that high levels of circulating DNA in blood
does not necessary reflect malignancy. It can also be the product of any
pathological process involving apoptotic and necrotic cells, such as inflam-
matory diseases and tissue trauma [85]. Another source of circulating DNA
is the fetus of pregnant women [87, 88]. By studying the presence of Y-
chromosomal DNA in the blood stream of women carrying a male fetus, it is
easy to distinguish fetus DNA from mother DNA and to study the dynamics
of circulating DNA. Sequential sampling of eight women that had delivered
male babies showed a rapid clearance of fetal DNA with an estimated mean
half-life of 16.3 min (range: 4-30 min) [89]. These studies were made during
the end of the 1990’s and since then, the technology has been more sophis-
ticated and recently, a paper was published where whole-genome sequencing
of mother, father and the circulating DNA from the mother had been carried
out, making it possible to reconstruct the genome of the unborn fetus [90].
The degradation process of circulating DNA is not yet fully understood but
experiments have shown that different forms of DNA survives for different
amounts of time. By injecting purified DNA into mice, a longer survival
of double stranded DNA (dsDNA) than single stranded DNA (ssDNA) was
observed. It was also demonstrated that a closed ring survived longer than
linear DNA [91]. Nucleases active in the blood stream have been proposed to
be the major source of degradation together with the liver and macrophages
as well as the kidneys since foreign DNA has been observed in the urine of
both pregnant women and cancer patients [85].
Quantifying the total amount of circulating DNA present in the blood of
a cancer patient cannot provide evidence of disease progression nor progno-
sis alone because of the large variation among individuals. Nevertheless, it
has been shown that the total level of circulating DNA decreases after suc-
cessful radical surgery and from response to chemotherapy [92]. The key to
use blood as a liquid biopsy is to be able to discriminate between tumor DNA
and normal DNA in some way.
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As mentioned in chapter 1.2, the most common form of genetic variation
is single nucleotide substitutions. This is also valid for tumors so looking for
tumor specific SNV’s in the circulating DNA content is a commonly used
way of detecting tumor derived DNA and this was also the first character-
istic used [82, 83]. KRAS is the most commonly assessed gene for detection
of tumor specific SNV’s in circulating DNA studies followed by TP53 (see
table 1.2). Other types of alterations used are structural rearrangements,
CNV’s, microsatellites and methylation. One of the greater challenges when
Gene Publications
KRAS 36
TP53 28
APC 4
NRAS 1
Table 1.2 Number of published studies up until 2007 where
the respective gene was assessed for tumor DNA detection in
plasma/serum and other body fluids using SNV’s. Data obtained
from [85].
detecting circulating tumor DNA is the relatively high levels of background
DNA derived from normal cells and this puts a high demand on the technical
approaches used. Also, different types of genetic variation provides different
conditions for detection and have also various potential of reaching satisfying
sensitivity and specificity.
Assessing tumor dynamics by monitoring tumor DNA in blood samples has
great potential for improving clinical practice. If a genetic profile of a tumor
is made, an assay specific for that particular tumor can be designed and ap-
plied for monitoring of the disease [80,81,93,94]. This could enable tracking
of a patient’s response to various treatments, early detection of relapse and
more reliable prognosis. Having these possibilities, choice of treatment and
dose can be individually adapted avoiding over treatment and unnecessary
side effects. For instance, radio therapy of breast cancer patient has been
correlated to increased risk of ischemic heart disease [95]. Circulating tumor
DNA has also been used for detecting acquired resistance to treatment by
screening for KRAS mutations in colorectal cancer patients subjected to anti-
EFGR therapy [96, 97]. Its utility as a biomarker for monitoring treatment
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response within metastatic breast cancer patients has been benchmarked
against other biomarkers such as cancer antigen 15-3 (CA 15-3) and circulat-
ing tumor cells showing that it is both more sensitive and more informative
than the others [98].
Another challenge for the utility of circulating tumor DNA is the hetero-
geneous nature of primary tumors. Most solid tumors consists of a multi-
tude of genetically different sub-clones [40] all of which might differ in their
abilities to shed nucleic acids to their surroundings [85]. The tumor DNA
measured in the blood is a mixture of the emissions from all tumor cells
and its composition reflects both mutation prevalence within the tumor and
the DNA secreting activity of the respective sub-clonal tumor cells. When
assessing a tumor’s genetic profile by sequencing a biopsy specimen, there
is a risk that the biopsy missed the part of the tumor that contributes the
most to the circulating DNA content and sequentially, when using this ge-
netic profile for monitoring tumor dynamics the outcome might be erroneous.
Circulating tumor DNA can also be used for screening of low-frequent muta-
tions within known oncogenes, enabling detection of tumors at an extremely
early stage. In contrast to detection of pre-determined mutations, the posi-
tions of the mutations in a screening situation are unknown and the statistical
significance level has to be adjusted accordingly making it harder to detect
ultra-low frequent variants. In a study using targeted ultra-deep sequencing
of plasma samples investigating a region of 5,995 bases, allele frequencies
of 2% were confidently detected and mutations previously missed by biopsy
sequencing could be identified [99].
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Chapter 2
Technology
For every leap in technology, a leap in biological knowledge follows. This is
only natural since understanding builds on making observations and drawing
conclusions. If a new technology enables previous unable observations, these
will be followed by previously undrawn conclusions.
2.1 Amplification
The ability of making copies of DNA molecules has been the key to modern
DNA science. This process is commonly referred to as amplification and
there are several methods for achieving this, both in vivo and in vitro, all
with different abilities, implications and limitations. Not only enabling a
stronger signal when interrogating DNA in different ways but amplification
is also a way of lowering the complexity by targeting and only copying the
region of interest.
Cloning
The first step towards the ability of copying DNA was taken in 1972 when
antibiotic resistance was transferred to a strain of E. coli [100]. This was the
beginning of molecular cloning and the following year, the use of a plasmid
for carrying the genetic material into the hosting organism was demonstrated
[101]. The term clone is said to be derived from the Ancient Greek and means
"twig" (a thin terminal branch of a tree) and it was introduced in analogue
to the phenomenon of growing a new tree by planting a twig. By transfecting
cells with a piece of DNA coupled to a gene vital for surviving in the growth
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environment, such as antibiotic resistance, this piece is copied as the cells
multiplies and will be present in all resulting cells. This amplification is
clonal meaning that within each resulting colony, all cells will be carrying
the same piece of DNA received by their common ancestor by transfection.
Until the mid-80’s, this was the main amplification method used by the
scientific community and it is a tedious and time-consuming process.
Polymerase chain reaction
In the discussion section of a paper about the replication properties of DNA
polymerases, the norwegian scientist Kjell Kleppe described how a cyclic
thermal reaction and a two-primer system could replicate a specific strand of
DNA [102]. This was in 1970 and probably because of the lack of an effective
way of synthesizing oligonucleotides in a sufficient scale to be used as primers
at that time, he was never able to test his theory in real life.
Instead, it was a californian biochemist named Kary Mullis that experimen-
tally proved the method in 1987 and he named it polymerase chain reaction
(PCR) [103]. He was awarded the 1993 Nobel prize in chemistry for this
achievement. In the article describing PCR, the mesophilic (likes moder-
ate temperatures) enzyme Klenow fragment of E. coli DNA polymerase I
was used and since it was destroyed in the heat of the denaturing step, new
enzyme had to be added for each cycle. This made the process very time
consuming and expensive and it was not until the thermophilic enzyme Taq
DNA polymerase was brought into use that the full potential of the method
was released [104].
PCR is a thermal cyclic reaction where each cycle consists of three steps
conducted at three different temperatures and theoretically, the number of
DNA molecules is doubled for each cycle resulting in an exponential ampli-
fication. The reaction is usually cycled 15-30 times giving 215 - 230 = 32,768
- 1,073,741,824 copies.
The specificity of PCR is established by the requirement of the primer-pair
being complementary to the flanking regions of the amplification target. If
one primer miss-anneals to another genomic region, this will result in a linear
amplification generating a low-yield product and the risk of this happens is
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relative high. Nevertheless, the risk of having miss-annealing to two regions
close enough to each other to facilitate exponential amplification generating
a high-yield bi-product is relatively low [104]. This risk is increased if several
primer-pairs are present in the reaction for a multiplex amplification which
is also the risk of primer-dimer formation. The latter is when two primers
partly anneals to each other and creates a short highly effectively amplified
by-product which tends to steal chemical capacity from the main reaction.
In summary, PCR has fundamentally revolutionized the filed of molecular
biology. Today, there is not a single biotechnological facility without a PCR-
machine.
Multiplex amplification
By adding several primer pairs to the PCR, a multitude of genomic regions
can be amplified simultaneously saving time, DNA sample and reagents. The
primer design for a multiplex PCR however requires significantly more at-
tention relative a simplex reaction. All pairs must be suitable for one com-
mon annealing temperature and if all the products should be distinguishable
in an electrophoresis analysis, it is preferable that they all have different
sizes. As mentioned above, the probability of having by-products increases
with the degree of multiplexity which further complicates the primer design.
Another phenomenon seen in multiplex PCR is recombination between the
different amplicons resulting in chimeric products [105]. Multiplex PCR was
first described in 1988 in a setting for detecting deletions in the dystrophin
gene causing the severe muscle degrading disorder Duchenne muscular dys-
trophy [106].
One of the most famous applications of multiplex PCR is DNA profiling for
forensic and relationship testing. These tests rely on a genetic feature called
short tandem repeats (STR) which are short repetitive sequence elements
of 3-7 nucleotides. STR’s are scattered all over the genome and because
the number of repeats differs between individuals, these are a rich source
of highly polymorphic markers distinguishable by size separation [107–109].
Today, the Swedish National Laboratory of Forensic Science (SKL) uses mul-
tiplex PCR for amplifying 16 different regions (15 STR’s plus Amelogenin
for sex determination) and four-color fluorescent aided detection by capillary
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electrophoresis. The risk of two siblings having matching profiles using this
kit is 1 in 50,000 [110].
It is hard to design a multiplex PCR for more than about 20 amplicons
due to by-product formation and primer-dimer amplification. For amplifica-
tion of a greater multitude of targets, like hundreds or even thousands, some
kind of mechanism has to be used for repressing the formation of unwanted
products and favoring amplification of targets. Several methods for highly
multiplex amplification have been developed and there is always a tradeoff
between the amount of unspecific products formed and the fraction of targets
that are amplified.
Molecular inversion probes (MIP) uses a circularization procedure of
the target molecules by hybridizing target specific ends of a probe on each
side and then joining the ends by fill-in followed by ligation (early versions
only relied on ligation). Remaining linear DNA is degraded and the circu-
lar probes are opened and amplified using universal primers [111]. MIP’s
have been implemented in a variety of applications such as SNP genotyp-
ing [112, 113], CNV profiling [114] and exome enrichment (55,000 targets in
one single reaction) [115,116].
The company Illumina have developed a method named Golden Gate for
multiplex amplification and genotyping. At genomic level, an allele specific
extension from probes carrying allele specific amplification handles is carried
out followed by ligation to a counter oligo carrying a SNP specific address
tag plus another universal amplification handle. The ligated products are
then amplified using three universal primers: two labeled with fluorescent
dyes matching the two allele specific probes and a third complementary to
the amplification handle of the address tag probe [117]. The capacity of this
assay is currently 3,072 SNP’s per reaction and 96 reactions (samples) in
parallel generating almost 300,000 genotypes per run.
Another method for multiplex amplification is trinucleotide threading
(TnT) which shares the end-joining strategy with the MIP’s, but by re-
stricting the extension to contain only three out of the four nucleotides, an
extra requirement to be fulfilled in order for end-joining to occur is intro-
duced [118]. This method has been applied within SNP-genotyping, targeted
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expression profiling and STR genotyping [119–121].
Emulsion PCR
PCR does not provide clonal amplification since its product is a mixture
of copies from a variety of starting molecules. Nevertheless, PCR can be
used for clonal amplification by compartmentalizing the reaction into micro-
scopic reactors containing only one starting molecule through the creation of
a water-oil emulsion [122]. Emulsion PCR (emPCR) is heavily used prior to
massive sequencing within many of the leading sequencing platforms today
(such as 454, SOLiD and Ion Torrent). Another application of emPCR is
amplification of complex libraries, like whole genomes, using universal am-
plification handles ligated to the template molecules. This can be done using
conventional PCR as well but with the risk of introducing bias by size dis-
crimination and product recombination [123].
2.2 DNA sequencing
The process of determining the sequential order of the nucleotides that con-
stitutes a DNA molecule is called sequencing. During recent years, the de-
velopment of sequencing machines regarding throughput and per-base cost
has proceeded beyond Moore’s law, a comparison often used for describing
something developing at exponential rate. In 1965 Gordon E. Moore, co-
funder of the company Intel, predicted that the number of transistors fitted
on a integrated circuit will double every two year (in the paper from 1965,
he actually stated one year but later revised it to two years) [124].
In figure 2.1 the development of sequencing costs at a major genome center
since 2001 is shown. Until the end of 2007, the development follows Moore’s
law but between Oct-07 and Jan-08 this trend was broken. Until then, the
sequence data was generated with capillary electrophoresis instruments but
when the next generation sequencing instruments entered the market, the
development accelerated. The observant reader notices the slightly increase
between Jul-12 and Oct-12 and this is probably due to lack of machine per-
formance upgrades and increased costs related to personnel, administration
and consumables.
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Figure 2.1 The development of sequencing costs in comparison
to Moore’s law. Data obtained from [125].
Electrophoresis
The history of sequencing starts long before 2001 when the first draft of
the human genome was released and even before 1977 when the fist effec-
tive sequencing methods and the first genome were published. It actually
starts in 1937 when Arne Tiselius, a chemist stationed in Uppsala, used elec-
trical current to separate the proteins within a blood sample in a device he
called electrophoresis apparatus [126]. In 1952, Markham and Smith used the
method to separate digested RNA into distinct bands revealing the length of
the molecules [127] and after some improvements by others, such as using a
starch or polyacrylamide gel [128, 129], size separation by electrophoresis is
one of the most frequent used methods for analyzing nucleic acids.
The principle of nucleic acid electrophoresis is to take advantage of the nega-
tively charged backbone. The sample is loaded in a well on a gel and an elec-
trical current is applied making the negatively charged nucleic acids migrate
towards the positively charged terminal. The size of the molecule determines
how fast it migrates so that short molecules will travel a longer distance than
long molecules within a specific time. Factors to vary for affecting the mi-
gration speed of a sample is the density of the gel, where molecules will move
slower in a more dense matrix, and the electric field intensity (determined
by the applied voltage and the distance between the electrodes, unit: V/m)
2.2. DNA SEQUENCING 29
where a higher intensity makes the molecules migrate faster. The most com-
mon way of visualizing the migrated DNA is by staining the gel using a dye
which binds to the DNA molecules and fluoresce when exposed to ultraviolet
light. Preferable, the fluoresce is highly intensified when the dye is bound to
a DNA molecule compared to unbound dye.
1977 and beyond
Since electrophoresis was the most delicate way of analyzing nucleic acids, a
lot of scientists must have deliberated on how it could be used for resolving
the mutual order of the four DNA bases that constitutes a DNA polymer.
The molecular tools for DNA manipulation available in the mid-70’s were
basically what we have access to today, such as restriction enzymes, ligases,
exonuclease and DNA polymerases (see table 2.1). The key was to generate
DNA fragments of various length coupled to the base composition so that
they upon size separation could reveal the DNA sequence. Fredrik Sanger
Enzyme Action on DNA Year Reference
Polymerases polymerization 1956 [130]
Exonucleases degradation 1960 [131]
Restriction enzymes cleavage 1965 [132]
Ligases joining 1967 [133–136]
Table 2.1 The most important components of the molecular
toolbox for DNA manipulation and their year of discovery.
presented a method for achieving this already in 1975 denoted "plus and mi-
nus sequencing". The idea was to generate fragments of all possible lengths
by letting a polymerase extend a growing DNA strand from a primer under
suboptimal conditions so that extension was very slow and asynchronous.
The product was then divided into 2x4 parallel reactions omitting one of the
four bases in one set of reactions (minus) and having only one of the four
bases present in the other set of reactions (plus). This disrupts the extension
at different sites depending on the bases present in the specific reactions and
generates molecules of all possible discrete lengths. Size separation by poly-
acrylamide gel electrophoresis (PAGE) revealed the sequence of the template
molecule [137]. The introduction of PAGE was a key for allowing sufficient
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resolution for separating longer fragments and achieving longer read lengths
(about 50 bases) and Sanger used this method for sequencing the fist genome,
which was that of the bacteriophage phi X174 consisting of 5,375 bases [138].
In 1977, two new methods for DNA sequencing were presented. Gilbert
and Maxam solved the puzzle without the use of enzymes by employing
chemical treatment for cleavage of the backbone at base specific sites (even
thou enzymes may have been used in the labeling process and for generating
the template molecules). By dividing a sample of a 5’-radioactively labeled
DNA strand into four reactions of different chemical environments restrict-
ing cleavage to A, A+G, C and C+T respectively, they generated fragments
of various distance between the 5’-probe and the cleavage point. After size
separation by gel electrophoresis, the sequence of the molecule could be re-
vealed [139]. This way of sequencing was preferred before Sanger’s plus and
minus method since Sanger’s approach was more tedious and could not han-
dle homopolymers in a satisfactory way [140].
However, these drawbacks were circumvented in Sanger’s second method,
published in december 1977, in which the chain terminating function was
trusted upon dideoxynucleotide triphosphates (ddNTP), nucleotide analogs
which are incorporated to the growing DNA chain as normal nucleotides but
hinders further extension. By splitting the template sample into four reac-
tions, each of which containing all four native nucleotides and a small amount
of one the four ddNTP’s, fragments of all possible discrete lengths are gen-
erated and the read-out can be done using PAGE [141]. The introduction
of ddNTP’s as chain terminators allowed even longer reads (about 100-200
bases) and individual read-outs for all residues of homopolymeric regions.
This method, known as Sanger sequencing, have been widely used and the
improvements regarding read length and throughput done in the 80’s, such
as using fluoresce labeled primers or ddNTP’s and automated capillary elec-
trophoresis [140, 142], made sequencing the human genome feasible. Today,
Sanger sequencing is the golden standard of sequencing methods and with
its high accuracy (>99,9%) it is often used to confirm findings from other
more high throughput methods.
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Pyrosequencing
During his post-doc period in Cambridge 1986, the swedish chemist Pål
Nyrén came up with the idea of sequencing by following the activity of a
nucleotide incorporating polymerase in real-time by analyzing its release of
pyrophosphate (PPi) [143]. This could be done using a series of enzymatic re-
actions for converting the released PPi into light and by adding one nucleotide
at a time in a cyclic manner while observing whether light was emitted or
not, the sequence of the growing DNA chain could be deciphered. It took Pål
ten years to develop a working protocol for pyrosequencing, much because of
funding issues. Finally, the reaction included four enzymes and steps: i) a
DNA polymerase incorporates a nucleotide and releases PPi which is used
by ii) ATP sulfurylase for converting adenosine phosphosulphate (APS)
into adenosine triphosphate (ATP) which drives the light emitting oxidation
of luciferin into oxyluciferin conducted by iii) luciferase, an enzyme isolated
from fire flies. Finally, all remaining nucleotides and ATP is degraded by iv)
apyrase before the next cycle is initiated. The intensity of the emitted light
during a cycle is partial proportional to the amount of accessible PPi which
makes homopolymeric regions detectable up to a certain limit [144,145].
The main factors limiting the read length of pyrosequencing are incomplete
incorporation of nucleotides to all template molecules which causes some of
them to fall behind (minus frame-shift) and incomplete degradation of the
remaining nucleotides resulting in some template molecules having too many
incorporations in the next cycle and thus gets ahead (plus frame-shift). Fore-
ach cycle, more and more molecules will come out of frame causing higher
noise and lower signals. In addition to this, accumulation of the by-products
sulphate and oxyluciferin inhibits the activities of ATP sulfurylase and lu-
ciferase making the pathway from PPi to light slower with the effect of a
longer lasting light signal at lower intensity. The nucleotide degrading en-
zyme apyrase is inhibited by its product deoxynucleotide monophosphate
(dNMP) which also causes the DNA polymerase to work slower and the de-
creased activity of both these enzymes results in increased frame-shift [146].
Even though pyrosequencing does not perform as well as Sanger sequenc-
ing regarding read length and throughput, it is less labour intensive with
shorter turnaround time and has found its use for several applications such
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as SNP analysis [147], forensic mitochondrial DNA typing [148] and methy-
lation analysis [149].
2.3 Next generation sequencing
As seen in figure 2.1, the sequencing market took a new turn during the
second half of the 00’s. The keys to this paradigm shift were miniaturiza-
tion of reaction volumes and parallelization. Before this, sequencing was
conducted in microliter reactors, 96 in parallel, but now it became possible
to run millions or even billions of parallel reactions in tiny reaction ves-
sels. At present, there are four sequencing platforms on the market: 454,
SOLiD, Illumina and Ion Torrent. Since the release of the ABI 370A
DNA sequencer in 1986 [140], the sequencing market was dominated by Ap-
plied Biosystems and their capillary sequencing machines and when these
massive parallel sequencing technologies were announced, they became de-
noted "Next Generation Sequencing". Even if these technologies today are
the present generation, they have become synonymous to the term "next
generation" and some have argued to stop using it. But since everybody in
the field know what is means, there is no reason to hinder its use. Figure 2.2
shows the dramatic increase in using next generation sequencing.
A common feature of all these technologies is that they rely on clonal am-
plification prior to sequencing in order to achieve sufficient strong signals for
base calling. To enable this amplification, universal amplification handles
need to be incorporated at both ends of the DNA molecules to be sequenced,
a process commonly referred to as library preparation (see section 2.4). An-
other feature, common for the three former platforms, is the use of an optical
sensor for detecting light generated by various sequencing chemistries.
454
The first instrument to enter the market of massive parallel sequencing plat-
forms was the Genome Sequencer 20 (GS20) by 454 Life SciencesTM which
was released in 2005. By performing pyrosequencing optimized for solid sup-
port and picolitre-scale volumes, the instrument was capable of generating
300,000 reads of 100 bases in each run [150]. Since then, the platform has
been upgraded several times enhancing both read length, error rates and
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Figure 2.2 Number of hits per year in PubMed from the search
string: "next generation sequencing". The triangular point of 2013
is an estimate based on the number of 2013 hits so far.
throughput. The latest version, named GS FLX Titanium XL+, is capable
of generating one million reads with a length of up to 1,000 bases (mean 700
bases) in a 23 hour run [151]. In 2009, the GS FLX+ system got a smaller
sibling when the bench-top instrument GS Junior System was released and
today it is capable of producing 100,000 reads with an average length of 400
bases in a 10 hour run [152].
As mentioned, 454 uses pyrosequencing chemistry. The genomic DNA to
be sequenced is fragmentized through nebulization, end-polished, phospho-
rylated and adaptors are ligated to the ends. The library is then immobilized
onto microscopic magnetic beads for clonal amplification by emPCR. Next,
the emulsion is broken and the DNA carrying beads are collected and spread
on a PicoTiterPlate which consists of millions of picolitre sized wells just
big enough to fit one single bead [153]. The bottom of the plate is trans-
parent, allowing a charge-coupled device (CCD) image sensor recording the
light emissions.
454 has been able to solve many of the limiting factors concerned with pyrose-
quencing. The accumulation of enzyme inhibiting byproducts is eliminated
since the reaction is performed in a fluidics system which facilitates wash-
ing procedures between the cycles. In order to save reagents, the enzymes
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luciferase and ATP sulphurylase are immobilized onto even smaller beads,
embedding the DNA covered ones so that they can remain in the plate during
the washes. The DNA polymerase is not washed away because it is bound
to the primed DNA templates. These improvements have contributed to the
enhanced read lengths that the 454 is capable of compared to conventional
pyrosequecing, which was conducted in standard reaction wells.
The major sequencing errors in the 454 sequencing platform are indels, es-
pecially in homopolymeric regions [154]. This is because the light signal
produced from the enzymatic pathway, when bases are incorporated, is not
perfectly linear to the amount of available PPi and the longer stretch of
equal bases, the harder the signal is to be interpreted by the base-calling al-
gorithm. The long reads and relatively short run duration is 454’s advantage
over the other platforms, especially for assembling low-complex regions when
sequencing genomes de novo [155] and in metagenomics [156]. However, the
read lengths of the competing platforms are increasing and their introduction
of table-top sequencers capable of quick runs will make it difficult for 454 to
live long and prosper.
Illumina
"... But they were all of them deceived for another method was made.
In the land of Massachusetts, in the labs of Cambridge Chemistry De-
partment, the scientists Shankar Balasubramanian and David Klener-
man developed in secret a master method, to control all others and into
this method, they poured their geniality, their illumination, and their
will to dominate all other sequencing methods. One method to rule
them all."
adapted from J.R.R. Tolkien, 1954
In the summer of 1997, the two colleagues Shankar Balasubramanian and
David Klenerman discussed how the fluorescently labeled nucleotides they
were working with at the time could be used for massive parallel sequenc-
ing of short reads on a clonal array. They worked at Cambridge University
and were inspired by the achievements within the filed of DNA research that
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Figure 2.3 The sequencing market shares in October 2012 ac-
cording to a reader survey done by In Sequence. Data obtained
from [157].
had been accomplished previously by people like Alexander Todd1, James
Watson2, Francis Crick2, and Frederick Sanger3. After receiving initial fund-
ing, the journey begun: they formed the company Solexa in 1998, acquired
Manteia’s molecular clustering technology in 2004, sequenced the genome of
phiX-174 (same bacteriophage as Sanger in 1977) in 2005, launched their first
instrument in 2006, was acquired by Illumina in early 2007 and sequenced
the human genome in 2008 [157,158].
Today, Illumina is by far the most widespread sequencing platform and ac-
cording to a reader survey by In Sequence performed in october 2012, they
hold 66% of the sequencing market (see figure 2.3) [159]. The method, com-
monly referred to as sequencing using reversible terminators, uses fluores-
cently labeled nucleotides which are blocked for further extension and hence,
only allows for one nucleotide being incorporated per cycle. But prior to
1Worked with synthesis and structure of nucleotides, awarded with the Nobel Prize in
Chemistry 1957.
2Co-discoverer of the structure of DNA, awarded with the Nobel Prize in Physiology
or Medicine 1962.
3Inventor of the Sanger sequencing method and determined the structure of various
proteins, insulin among others. Was awarded the Nobel Prize in Chemistry 1958 for the
latter and the Nobel Prize in Chemistry 1980 for the former.
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the actual sequencing reaction, the DNA sample must be processed into a
sequencing library and clonally amplified. The library preparation includes
random fragmentation, end-polishing, phosphorylation and adenylation fol-
lowed by adaptor ligation and enrichment of ligated fragments by PCR (see
chapter 2.4 for details). In this process, sample specific identification tags
are incorporated so that several samples can be sequenced together but still
have separate data files.
After quantification, the sequencing library is diluted to an appropriate con-
centration, made single stranded by adding NaOH and spread on the flow-
cell surface for formation of a clonal single molecule array. The flow-cell
is covered with surface bound oligonucleotides complementary to the ligated
adapters which allows the single stranded DNA to anneal. The surface bound
oligonucleotide primes an extension reaction forming a copy of the template
molecule covalently attached to the flow-cell surface and the original strand
is then denatured and washed away. The adapter sequence at the free end of
the copied strand is then annealed to another complementary surface bound
oligonucleotide which primes another extension reaction forming a bridge.
When the product is denatured, both ssDNA molecules remains on the sur-
face and can form bridges for another cycle of amplification. Thermal cyclic
reaction conditions allows for several rounds of denaturing, annealing and
extension which generates clusters of molecular copies [158, 160]. In the Ill-
munina sequencing platform, the bridge amplification is managed by a so
called cBot which is an automated system for cluster generation.
The flow-cell is then transferred to the HiSeq instrument for sequencing
by synthesis. In contrast to pyrosequencing, where only one nucleotide is
present in each cycle, all four nucleotides are subjected to incorporation in
sequencing using reversible terminators. This is made possible thanks to the
base specific fluorescent label which facilitates identification of the incorpo-
rated nucleotide. Since each nucleotide carries a blocking group bound to the
3’-carbon of the sugar unit, only one nucleotide is incorporated in each cy-
cle and the incorporation reaction can be driven to completion without risk
of over-incorporation [158]. Once the incorporation is complete, the base
is determined by fluorophore excitation by laser and CCD camera imaging.
Prior to the next cycle, the blocking group and the fluorophore are chemi-
cally cleaved off from the nucleotide leaving a 3’-hydroxyl group suitable for
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another incorporation. Once the read is completed, usually after 101 bases,
the product is denatured and removed and the remaining strand is used for
generation of another bridge and the template for a second read is synthe-
sized.
The main reason for low quality reads is over-clustering which means that too
many ssDNA molecules were spread on the flow-cell surface generating mixed
and overlapping clusters that are hard to interpret for the base-calling algo-
rithm. The most abundant sequencing errors are substitutions and specific
sequences, such as inverted repeats and GGC regions, have been shown to be
more prone to errors [161]. The suggested mechanism behind the sequence
specific errors is secondary structure formation from base pairing within the
ssDNA molecule resulting in a hair-pin structure that blocks the DNA poly-
merase and hinders complete nucleotide incorporation.
Currently, Illumina has five sequencers in their program (see table 2.2) and
provides kits for several kinds of applications like whole-genome sequenc-
ing, targeted sequencing, RNA-sequencing, methylation analysis by bisulfite
sequencing and protein-DNA interaction analysis by ChIP-seq. The combi-
nation of medium read lengths, high quality paired-end reads and a massive
throughput has made Illumina the system of choice for a vast majority of the
sequencing project conducted around the world.
HiSeq 2500/1500 HiSeq 2000/1000 MiSeq GAIIx HiScanSQ
Output (Gb) 600/300 600/300 8.5 95 150
Run time 27h-11 days 8.5-11 days 4-39h 14 days 8.5 days
Single reads (Billion) 0.3-3 3-6 0.017 0.32 0.75
Read length (bp) 100-150 100 250 150 100
Table 2.2 Illumina’s current line-up of sequencers as of March
2013.
SOLiD
The 3rd platform to hit the next generation sequencing market was released
in 2007 and is based on sequencing by oligonucleotide ligation and detec-
tion (SOLiD). This is the only commercially available sequencing platform
today that does not include a DNA polymerase in its sequencing reaction
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but instead relies on a DNA ligase [162]. However, the introduction of uni-
versal adaptors through library preparation and a clonal amplification by
emPCR prior to the sequencing is shared with the others. The sequenc-
ing method, originally denoted polony sequencing, was developed at Harvard
Medical School in Boston by Greg Porreca and Jay Shendure under super-
vision of George Church during the mid-00’s and was later adapted to the
SOLiD platform by the company Applied Biosystems.
The sequencing reaction is conducted on the microscopic magnetic beads
used in the emPCR that are covalently bound to the surface of a glass slide
through 3’-modifications of the emPCR products. The sequencing reaction
starts by hybridizing a randomized DNA probe next to a sequencing primer.
If the two bases closest to the primer match the template DNA strand, the
probe can be ligated to the primer and remaining non-matching probes are
washed away. The probe has a fluorescent label specific to the two dis-
criminating bases that is recorded before half the probe, including the fluo-
rophore, is cleaved off for another round of sequencing. Since there are two
discriminating bases, SOLiD uses a two-base encoding system consisting of
16 different base combinations labeled with four different colors and in order
to decipher a base, the combined color information of two probes is used.
This basically means that each base needs to be sequenced twice in order
to be identified but on the other hand, this system gives a very low error
rate. Since a ligation reaction is used, sequencing can be done in both direc-
tions of the primer which is not possible when using a DNA polymerase [163].
In the newest instrument, the 5500 W Series Genetic Analysis System, an-
other approach for clonal amplification prior to sequencing is offered. Through
a isothermal process, the DNA library is amplified directly on the FlowChip.
Like in bridge amplification, oligos that are attached to the surface func-
tions as primers for annealed template molecules. After extension, instead
of annealing the 3’-end of the newly synthesized strand to a new surface
bound primer, the template strand switches primer from the extended to a
non-extended. At the same time, a free primer is added to the 3’-end of the
newly synthesized strand so that both strands of the first product is copied
in the second cycle. This method, called Wildfire template walking, produces
colonies suitable for sequencing and allows for a more efficient sequencing
reaction that consumes less reagents and a higher density on the sequencing
2.3. NEXT GENERATION SEQUENCING 39
chip resulting in more data at lower cost. This system is capable of producing
320 Gb of data in a single run from 2x50 bp reads [164].
Ion Torrent
The latest addition to the sequencer market was the Ion Torrent platform,
released in 2011. This is the only commercially available sequencing tech-
nique today that uses neither light nor optics in its base detection system. In
stead, a semi-conductor chip is used to detect the alteration in pH following a
proton (H+) release when a base is incorporated [165]. Like in pyrosequenc-
ing, the method relies on subjecting natural nucleotides to incorporation,
one base at a time in a cyclic manner, and then detect if incorporation took
place or not. This means that several nucleotides can be incorporated within
the same cycle in homopolymeric regions and because of this, Ion Torrent
has inherited its predisposition of indel errors from 454 with an accuracy of
96.5% calling a 5-mer. However, the substitution error rate is less than 0.1%
and the mean accuracy of a 250-bp read is 99.7% [166]. The fact that the
sequencing chemistry entirely consists of natural reagents, enzymes as well
as nucleotides, the enzyme activity is kept at its best and the reagent cost
is low. Also the detection chip is cheap since it is based on CMOS processes
from standard electrical component production plants.
There are three different chips available for the Ion PGM (Personal Genome
Machine) sequencer named 314, 316 and 318. The different chips have dif-
ferent throughput and there are also several read-length options which gives
a multitude of choices when designing a sequencing experiment. The scala-
bility ranges from generating 3 Mb of data in 30 minutes using the 314 chip
and 35 bp reads to 2 Gb of data using the 318 chip and 400 bp reads in 7
hours and 21 minutes. This level of throughput makes the machine ideal for
applications like amplicon sequencing, SNP confirmation and small genome
sequencing. Another machine called the Ion Proton System was recently
made available for featured costumers and is currently capable of generating
10 Gb of data in a 2-4 hour run. Nevertheless, an upcoming chip is promised
to offer whole human genome sequencing at 20× coverage, from sample to
called variants, in less than a single day.
In conformity with other platforms, a library must be prepared and subjected
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to clonal amplification using emPCR prior to sequencing. Multiple copies of
the template in each reactor is needed so that the amount of released H+ can
reach detectable levels. However, emPCR is template consuming, expensive
and technically challenging so Ion Torrent have announced that they are de-
veloping a non-emulsion PCR protocol for producing templated beads called
Avalanche. This is based on local amplification on beads but without the
emulsion which is achieved by having one primer bound to beads and the
other in solution [166].
2.4 Preparing DNA for massive sequencing
The science-fiction movie "GATACCA" from 1997 sets in a not too distant
future where all humans are categorized by their genetic make-up. In one
scene, the female main character (Uma Thurman) visits a booth on the street,
where whole-genome sequencing and genetic make-up scoring is conducted,
for investigating a hair she just collected at the male main character’s (Ethan
Hawke) working desk. The dialogue between her and the man behind the
desk goes like:
- You want the full sequence?
- Yes.
20 seconds later he gives her a thick paper roll and reads from the first
line:
- 9.3. Quite a catch.
- Yes, quite a catch.
So, he just performed whole-genome sequencing, data analysis and risk as-
sessment in 20 seconds (not mentioning printing all 3 billion characters on a
piece of paper). Currently, we are not there (yet).
Today, this would take weeks and require a lot more DNA than what is
in a hair. The process from biological sample to interpreted sequence data
can be subdivided into five steps: i) DNA extraction, ii) library prepara-
tion, iii) clonal amplification, iv) sequencing and v) data analysis. Library
preparation is the process where the DNA molecules are adapted for the se-
quencing reaction by adjusting their length and adding synthetic sequences,
commonly denoted adapters, to their ends. In all next generation sequencing
platforms available today, library preparation starts with fragmentation of
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the DNA sample in order to generate short randomly sheared molecules and
this is followed by modification of the DNA fragments adapting them for
the sequencing reaction and finally quantification of the produced library.
As the amount of data generated by the sequencing machines have increased
and the sequencing costs have fallen, the library preparation step has become
a bottleneck for the sample throughput and has a relatively high impact on
the budget of a sequencing project.
Fragmentation
The concept of sequencing randomly sheared fragments is commonly denoted
shotgun sequencing and the term was used as early as 1979 when a paper
described the adaptation of computers for assembling shotgun reads into long
continuous sequences [167]. There are three ways of shearing DNA: by phys-
ical stress, enzymatic cleavage or chemical treatment. The most common
method in library preparation procedures is physical shearing by sonication.
Here, DNA is subjected to ultra-sonic sound waves in a sonicator and the
company Covaris provides an instrument where this can be done in small
vials and in downstream processing friendly solutions with relatively small
material loss. Other methods of physical shearing is nebulization that uses
gas pressure (used by 454) and hydroshearing that uses change in fluidic
pressure.
Enzymatic approaches relies on several enzymes which together cleaves the
DNA at random positions. New England Biolabs (NEB) sells a product
called dsDNA Fragmentase which is a mixture of two enzymes, one that ran-
domly nicks the dsDNA and one that recognizes the nicks and cleaves the
opposite strand. The sizes of the produced fragments are dependent of the
reaction duration. One advantage of using enzymatic shearing is that is is
easy to scale and automatize but enzymes requires the right buffer to work
optimally and this is not always compatible with downstream reactions and
a purification step might be needed in which some of the material is lost.
Modification
The purpose of the modification step is to incorporate the sequencing adapters
to the DNA molecules and to enrich for ligated fragments. But before liga-
42 CHAPTER 2. TECHNOLOGY
tion of sequencing adaptors can be made, the ends of the fragmentized DNA
molecules have to be repaired and commonly, also adenylated and phosphory-
lated. All these end-modifications are performed by enzymes that have their
own optimal reaction environment and temperature. But since all purifica-
tion steps involves loss of material, it is preferable to have as many enzymes
as possible within each reaction but without decreasing their reactivity by
deviating from optimal reaction conditions. This is further investigated in
paper III and is also discussed in chapter 3.3.
As mentioned, the ends of the fragmented DNA needs to be end-repaired
since they might have large 3’- or 5’-overhangs unsuitable for adaptor liga-
tion. This is commonly done using the enzyme T4 DNA polymerase which
fills the 5’-overhangs by extending from the innermost 3’-end and it also
exhibits 3’-exonuclease activity and degrades 3’-overhangs. This results in
blunt-ended DNA fragments which can be directly subjected to blunt-end
ligation. In order to ligate the 3’-end of one DNA strand to the 5’-end of
another strand, the 5’-end needs to be phosphorylated. For adaptor ligation,
one can have pre-phosphorylated adapters or phosphorylate the end-repaired
DNA, commonly using the enzyme T4 polynucleotide kinase (PNK) or both.
It is desirable to minimize adaptor-adaptor ligations and also ligation of two
end-repaired fragments. The former occurs in greater extent than the latter
since the adapters are short and often present in ten-fold molar excess. There
are several ways of avoiding this of which one is to use non-phosphorylated
adapters which cannot be ligated to each other. Another way is to use so
called AT-cloning where the end-polished DNA is adenylated which means
that one A-base i added to the 3’-end. This can be done using a DNA poly-
merase lacking 3’->5’ exonuclease activity such as Klenow fragment. Only
adapters having one complementary T-base at their 3’-end can then be lig-
ated to the A-tailed fragments but neither adapters nor A-tailed fragments
can be ligated to each other.
Once the fragmented DNA is prepared for ligation the adapters can be added.
When two kinds of adapters are used, here denoted A and B, in order to in-
corporate different synthetic DNA sequences at the different ends of the DNA
fragments, there are three possible outcomes of adapter combinations: frag-
ments carrying A and B, which is the desired, but also A-A and B-B carrying
fragments will be formed. This means that two thirds of the formed fragments
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will be useless and the yield from the ligation reaction will be low. However,
this can be circumvented, while still having different sequences added to the
ends, by ligating a Y-shaped adapter which is a adapter construct that is
complementary in one end (the base of the Y) but have different sequences
in the other end (the arms of the Y) [168].
After the ligation step, the DNA is basically ready for sequencing but since
the different enzymatic steps do not have 100% efficiency, only a minor frac-
tion of all fragmented DNA that was put in the modification process have
ended as complete library molecules. It is therefore desirable that the lig-
ated fragments are enriched and amplified by running PCR using primers
complementary to the ligated adapters. It is also common that barcodes,
enabling multiplex sequencing of several samples within the same lane, are
incorporated in this step through one of the PCR-primers. However, GC-
rich DNA-fragments are discriminated in the PCR-reaction since it is harder
for the DNA polymerase to extend through these regions and hence, bias is
introduced. To overcome this, methods for amplification-free library prepa-
ration have been developed where the discrimination between ligated and
non-ligated fragments is done on the flow-cell surface during cluster genera-
tion instead, but more input-DNA is required in order to generate sufficient
ligated molecules [169, 170]. Another problem introduced in the PCR-step
is the formation of PCR duplicates. If the PCR is allowed to run for too
many cycles, these will dominate the library and the sequencing data will be
mostly redundant.
Quantification
In order to load an appropriate amount of molecules to the clonal amplifi-
cation procedure (cluster generation or emPCR), it is important to quantify
the generated library correctly. In the Illumina instruments, the data quality
is highly dependent on an optimal cluster density since too dense clusters will
grow into each other, generating mixed signals, and too sparse clusters will
generate less data. DNA amounts can be measured by binding fluorescent
dyes to the DNA molecules and measure the fluorescence or by assessing the
absorbance using a spectrophotometer. The former is more accurate than
the latter since absorbance based approaches are more sensitive to contami-
nants. Both methods suffer from measuring the total amount of DNA in the
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sample with no possibility of discriminating between ligated and non-ligated
fragments nor primer-dimers and other short fragments [171]. Automated
capillary electrophoresis, like the Bioanalyzer by Applied Biosystems, offers
the possibility of analyzing both the concentration and size distribution of
the library. But in order to measure the exact amount of ligated fragments
one has to rely on a PCR-based approach such as quantitative PCR (qPCR)
in which only amplifiable molecules will generate a signal.
Library complexity
The effectiveness of the library preparation process and the amount of start-
ing material determines the complexity of the produced sequencing library.
Library complexity is defined as "the expected number of distinct molecules
that can be observed in a given set of sequenced reads" [172]. Figure 2.4 il-
lustrates a high complex library containing many kinds of point characters
and a low complex library containing an equal amount of points but only two
kinds of characters. In analog, a highly complex sequencing library contains
many unique kinds of randomly sheared, modified and amplified molecules
whilst a low complex library contains few unique molecules that have been
copied through PCR so that the mass of the libraries are equal. If the modi-
fication step of the library preparation process is inefficient, a relatively small
amount of the starting material will be available for amplification in the PCR-
step and to have sufficient molecules for the sequencing reaction, additional
PCR-cycles have to be run and the complexity of the library would dwindle.
Library complexity is hard to assess prior to sequencing since the quality
controls available are mainly quantitative but shallow sequencing prior to a
large run can give some indication [172]. When interrogating sequence data,
low-complex samples are shown as having a high proportion of PCR dupli-
cates. Aligned reads sharing genomic start and stop coordinates have likely
originated from the same template molecule and thanks to this, they can
be computationally identified and are often filtered away to avoid redundant
data. So, the proportion of PCR duplicates in a sequence data set depends
on the complexity of the sequenced library but it also determined by the
sequencing depth.
Consider the two libraries illustrated in figure 2.4. In a sequencing experi-
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high complexity low complexity
Figure 2.4 Illustration of high and low complexity sequencing
libraries.
ment, reads are drawn randomly from a library of molecules so imagine that
the points that illustrates molecules in the figure are randomly sampled. How
many points will have to be drawn before two equal characters are likely to be
observed? In the low-complex library there are only two different characters
so at the second attempt there is a 50% chance that the new character is of
the same kind as the first (assuming they are present in equal quantitates)
and when three points are drawn there is certain that at least two of these
are of the same character. This means that at a shallow depth of one and
two drawn points, the library can still have no duplicates but after a few
extra points, both kinds of characters present in the library are likely to have
been observed and all extra points are abundant. The high-complex library
consists of 20 different point characters so not until the 21st attempt there
is certain that two equal characters have been drawn.
In figure 2.5, two real libraries, one of high complexity and one of low com-
plexity, have been sequenced at a depth of more than 80 million reads. To
illustrate the sequence depth dependence on the proportion PCR duplicates,
these data sets have been subsampled at various depth and the proportion
duplicates have been calculated and plotted. Since the probability of ob-
serving new unique molecules decreases when more and more molecules are
observed, the gain of obtaining more reads becomes less when sequence depth
increases. As shown in figure 2.5, the number of unique molecules observed
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Figure 2.5 LEFT : the sequence depth dependence of observed
proportion PCR duplicates in high and low complexity sequencing
libraries. RIGHT : the increase of observed unique molecules at
higher depth is almost linear in the complex library but is early
saturated in the low-complex library.
becomes saturated already at a little more than ten million reads in the
low-complex library whiles the complex library almost show a linear relation
between sequence depth and observed unique molecules.
Complex sequencing libraries are highly preferable and are achieved by us-
ing large quantitates (micrograms) of starting material when preparing the
library. However, this is not always feasible, especially when working with
biological material coming from limited sources such as blood samples, tu-
mor tissue or biopsies. Under these circumstances, it is most desirable to get
as high complexity as possible. One way is to apply whole genome amplifi-
cation before library preparation but this technique comes with the risk of
introducing bias. Another way is by having a high yield library preparation
procedure. One of the most effective methods that are available today uses
an in vitro transposition procedure instead of the traditional fragmentation,
modification and ligation approach. In this method, a transposase enzyme
carries out both fragmentation and adapter ligation in one single step which
reduces the amount of input DNA needed down to as low as 100 pg [173]. This
technology is now sold by Illumina under the name Nextera and according
to its standard protocol, 50 ng DNA is sufficient for producing a highly com-
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plex library in 1.5 hours with only 15 min hands-on time. Another method
that uses the more traditionally enzymatic steps is the ThruPLEX-kit sold
by Rubicon Genomics. Here, a stem-loop adapter construct is blunt-end lig-
ated to the fragmented and end-repaired DNA molecules with high efficiency
and since its 5’-ends are blocked, the formation of adaptor-adaptor ligated
molecules is reduced. After ligation, the left-over adaptors are degraded and
amplification can be performed without any purification step.
Barcoding
Since the great capacity of todays sequencing instruments often exceeds
whats needed to answer the biological question behind a sequencing experi-
ment, the ability of analyzing several samples in the same run, but still be able
of analyzing the data as discrete samples, has proven to be of importance.
This can be achieved by introducing a molecular sample specific barcode,
which consists of a short sequence stretch situated next to the sequencing
primer region. The introduction can be done either through PCR [174, 175]
or ligation [176]. A method for using a combination of two tags when se-
quencing large sample sizes has been developed in paper I and is further
discussed in chapter 3.1.
2.5 Targeted sequencing
Experiments where only selected parts of genomes are analyzed are called
targeted sequencing. This is preferable when the biological question behind
the experiment does not require investigation of the whole genome but only
a pre-defined part. This sub-part can consist of for example a set of genes
involved in a biological pathway, all coding regions (whole exome), genes pre-
viously associated with a trait in a GWAS or protein binding regions. There
are several approaches for enriching the desired regions but the most used
commercial methods are based on either PCR or hybridization.
At first, hybridization selection was performed on a chip surface [177, 178]
with relatively low efficiency and complicated laboratory procedures but
when in-solution hybridization was presented [179], it became both better
and more accessible. In solution hybridization based approaches, sheared
and adapter ligated DNA fragments are allowed to hybridize to biotinylated
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probes of synthetic DNA or RNA, complementary to the target regions, of-
ten denoted "baits". The hybridization reaction is often allowed to run for
several days so that the molecules of the highly complex sample should have
time to find and hybridize to their complementary baits among all other bait
molecules in the highly complex bait library. Once the hybridization reaction
is completed, the target carrying bait molecules are bound to para-magnetic
beads through a biotin-streptavidin coupling and non-target molecules can
be washed away. Target molecules are then eluted and amplified. If the bait
molecules consisted of RNA, like in Agilent’s SureSelect technology, they can
be easily degraded by adding RNAse. The success of the enrichment process
can be assessed by runnig qPCR over selected control regions. A commonly
used measure of non-uniformity in coverage across the target regions is fold
80 base penalty. This estimates the fold extra sequencing needed to raise
80% of the targets above the average coverage. A low value means a uniform
sequence coverage and in general, less than 4 is considered good and exomes
often ends up around 3.
The three most established technologies for hybrid capture today are SeqCap
by NimbleGen, SureSelect by Agilent and TruSeq Enrichment by Illumina.
The largest differences between these technologies are the quantity of baits
and the density of the bait design. NimbleGen uses a highly dense and over-
lapping bait design covering the target regions several times, Agilent designs
the baits to reside immediately next to each others with 1x target coverage
and Illumina uses the most sparse design and relies on paired-end reads to ex-
tend the coverage outside the bait regions instead. In a direct comparison of
these three technologies’s performances in an exome sequencing experiment
done in 2011, NimbleGen’s dense design (>2.1 million baits) covered least
genomic regions (44 Mb) and required the least amount of sequencing to be
able to detect SNV’s and indels [180]. With additional sequencing however,
Agilent and Illumina could detect a greater total of variants (0.66 and 0.34
million baits covering 52 and 62 Mb respectively).
Since NimbleGen performed best regarding both target enrichment efficiency
and off-target enrichment (see table 2.3), this is the most cost-efficient tech-
nology. Today however, it is the sample preparation including sequence cap-
ture that is the most abundant cost and not the actual sequencing (unless the
target region is really large) so the best value for money is more dependent
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Platform Target size Baits >10x target cov Off-target
NimbleGen 44 Mb >2.1 million 96.8% 9.1%
Agilent 52 Mb 0.66 million 89.6% 12.8%
Illumina 62 Mb 0.34 million 90.0% 35.6%
Table 2.3 Comparison of exome sequencing performance using
a normalized depth of 80M mapped reads. The comparison was
made in 2011, data obtained from [180].
of which per-reaction price that can be negotiated from the respective com-
pany. Also, the balance between coverage and efficiency might be considered
regarding the demands from the biological question. For example, Illumina’s
exome design also includes the untranslated regions (UTRs) which might be
of interest.
Target enrichment can also be achieved through PCR, designed for both sin-
gle, hundreds and even thousands of amplicons. In contrast to the hybridiza-
tion based approaches, PCR performs the discrimination between target and
non-target regions directly on genomic DNA and hence, requires less input
material. As mentioned in chapter 2.1, it is troublesome to perform multi-
plex PCR when the number of amplicons increases. In order to amplify a
multitude of targets, an approach to prevent primer-dimers from dominating
the end-product must be applied. In chapter 2.1, methods for enriching and
amplifying SNP’s were discussed but there are also several methods for tar-
geting larger regions suitable for sequencing, some of which are kept secret
by the manufacturer of business reasons.
Ion Torrent provides a technology called AmpliSeq in which a multiplex PCR
is performed followed by a primer removal step using a secret reagent that
degrades the primers specifically. Since the duration of a run on the Ion
PGM is short (4 hours for 400 base reads) and the duration of a hybridiza-
tion capture is long (1-4 days), the bottleneck of sequence capture using
hybridization is inconveniently narrow. Motivated by this, Ion Torrent de-
veloped their own capture technology capable of processing a DNA sample
into a sequence ready capture library in less than 3 hours. This method
allows for amplification of up to 4,000 targets from as little as 10 ng DNA
followed by integrated library preparation and sequencing [166]. Ion Torrent
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offers both pre-designed panels like the Cancer HotSpot panel, the Inherited
Disease Panel and the Comprehensive Cancer Panel but it is also possible to
make own custom panels using their on-line design tool.
There are also several methods based on circularization. Agilent offers a
technology called HaloPlex in which the DNA sample is digested using re-
striction enzymes and a probe library hybridizes to the specific ends of the
target fragments and guides them to form a circle. The probes are biotiny-
lated and allows for target retrieval using streptavidin coated para-magnetic
beads. After closing the target circles by ligation, the library is amplified
by PCR in a way so that only closed circles becomes amplified [181]. As
mentioned in chapter 2.1, padlock probes can also be used for exome cap-
ture [115,116].
2.6 (n + 1)th generation sequencing
Since the term next generation is taken by the present generation, the term
(n+ 1)th generation may be used instead to address the actual coming gen-
eration. n+1 is derived from a mathematical method used for proving that a
given statement is true (or false) for all natural numbers. It is called mathe-
matical induction and it says that if a statement is true for any given number
n, it must also be true if n is replaced by n+ 1. In analog with the naming
of sequencing generations: if the present generation is generation n, the next
one will be generation (n+ 1).
Today, it is hard to categorize sequencing methods into distinct generations.
Some might claim that Ion Torrent belong to another generation than 454,
SOLiD and Illumina since there is no light involved in the detection sys-
tem (the post-light generation) whiles some might claim that Pacific Bio-
sciences (described below) should belong to this generation when regarding
its throughput capacity and light based detection. But everyone is right and
nobody is wrong and it might be so that the over-nite sensation seen during
the late 00s that has led to a paradigm shift in the field of sequencing will not
happen again. It is likely that emerging technologies are released when they
are still at an early state and then gradually developed over several years
before their full potential is reached, even though the emerging nanopore
technologies (described below) seem promising from the start.
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So, what is to expect from the emerging technologies? While the capac-
ity continues to increase, some new features will also be seen. Among the
ones that have already begun to appear are extremely long read lengths and
library-free sequencing. In 2009, the Californian company Pacific Biosciences
(PacBio) showed in a Science paper that they could sequence a DNA strand
by fixating a DNA polymerase at the bottom of a zeptoliter (10−21 liter) re-
actor and detect fluorescently labelled nucleotides in real-time as they were
being incorporated to the growing strand by the polymerase [182]. The tech-
nology is called single-molecule real-time (SMRT) sequencing and it uses an
engineered phi29 DNA polymerase immobilized in a zero-mode waveguide
(ZMW) which is a nano structure used for reaction confinement and enables
detection of nucleotides while they resides at the active site of the polymerase,
without the interference from surrounding nucleotides despite their high con-
centration. The fluorescent dye is attached to the terminal phosphate group
of the nucleotide and hence, is naturally cleaved off when the nucleotide is
incorporated. In 2011, the company introduced their first instrument, the
PacBio RS, to the sequencing market and it is today capable of generating
22,000 reads with an average length of 4,600 bases (up to 20,000) in 2 hours.
However, the base quality is relatively low with an accuracy of <90% at 1x
coverage [183]. However, by utilizing the exceptionally long read length, the
base quality can be improved by circulating the template to be sequenced
and allow the heavily strand displacing polymerase to loop through it several
times.
Oxford Nanopore Technologies is a company that develops a sequencing tech-
nology based on flowing a single DNA strand through a nanopore and record
the shift in current that occur when different bases passes through. The
company was formed in 2005 and when they revealed their system at the
conference AGBT (Advances in Genome Biology and Technology) in febru-
ary 2012, the first instrument release was scheduled to late 2012 but at the
writing moment (late Mars 2013), no system has yet been made available.
There were two instruments announced: the GridION and MinION systems.
The first is a electronics-based platform consisting of several GridION nodes
and can be scaled up like computer clusters but one single node can also
be used alone like a bench-top sequencer. The MinION applies the same
sequencing technique but in a miniaturized disposable device connected di-
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rectly to a laptop through a USB-port. According to the announcement, the
technology will be able to produce reads of 100 kb at launch and one Grid-
ION node will consist of 2,000 nanopores and later extended to 8,000 pores
of which each is capable of sequencing hundreds of kb per second. Theoreti-
cally, this would allow for sequencing the human genome in 15 minutes using
20 nodes. The technology was demonstrated by sequencing the entire 5.4 kb
genome of the famous phage phi X in one single read stretch with an error
rate of 4%. However, the company claims the the error rate will be improved
until release to around 0.1-1% [184].
Chapter 3
Present Investigations
The papers that constitutes this thesis all aim to overcome technical hurdles
arisen from biological questions. The common theme is the aim of making
investigation of DNA using sequencing more effective. There are four pa-
pers of which two (paper I & II) were conducted at the Royal Institute of
Technology (KTH) and two (paper III & IV) at Karolinska Institutet (KI).
In this chapter, the projects behind the papers are described and discussed
while trying not repeating what is written in the papers.
3.1 Paper I - dog tags
This work was initiated in 2008 when the division of gene technology at KTH
recently had gotten their first next generation sequencing instrument in their
hands, namely a 454 genome analyzer. This had off course generated a lot of
enthusiasm in the group and the ideas of technical methods taking advantage
of its high throughput were flowing.
Background
The read length of the 454 instrument makes it suitable for amplicon se-
quencing since relatively long amplicons can be read through in a single read
and its throughput opens up for investigating a large amount of samples at
once in the same run. Introducing sample specific molecular barcodes at
the ends of the molecules to be sequenced makes it possible to determine
the origin of a read and thereby demultiplexing the data by computational
methods [174–176]. What is limiting the amount of samples that can be
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investigated together is the availability of unique tags. To be able to sepa-
rate tags containing sequencing errors, it is preferable to design them so that
they differ at more than one position and because of 454’s predisposition to
indel errors in homopolymeric regions, these are also best avoided. It is also
preferable to keep the tags short so that they not occupy too much of the
reads. When taking these considerations into account, the number of unique
7 bp tags that can be obtained with a minimum of 2 substitutions is 173 and
with a minimum of 3 substitutions it is only 52 [176].
Today, Roche provides up to 132 multiplex identifiers (MID’s) and if larger
sample sets needs to be investigated on the 454, physical separation of sam-
ples can be achieved by applying an up to 16 region gasket. This facilitates
2,112 samples to be investigated within the same run but the gasket occupies
a significant amount of the sequencing space and preparing 16*132 sequenc-
ing libraries using the standard kits is both expensive and laborious.
Several methods circumventing these limitations have been proposed and
the overall achievement of these have been to sequence more samples than
unique tags used. In other words: addressing the linear increase of needed
tags when sample size grows. However, this has been accomplished by the
cost of increased complexity of sample handling with higher risk of human
errors which may result in erroneous sample tagging and biased data. One
such method is denoted DNA sudoku and relies on tagging groups of samples
rather than single samples and having each specimen present in two unique
groups. The groups are then pooled both row-vise and column-vise creating
a sample matrix where the total number of pools to be sequenced equals
to the number of rows times the number of columns. After sequencing, the
matrix can be solved using a computational method similar to the strategy
used when solving a sudoku and this makes it possible to associate a genetic
diversity to a single sample [185]. This approach greatly decreases the num-
ber of tags needed for a certain level of multiplexity but the experimental
complexity is large and the method is best suited for finding rare variants
within large sample sets.
A smart way of reducing the number of unique tags desired for a certain
experiment is by letting the combination of two tags be the key for associat-
ing reads to specimen. This was first done in 2010 by a french group that used
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tagged PCR-primers to introduce different tags at the two ends of the PCR
products so that every sample was given a unique tag combination [186]. Like
DNA sudoku, this method was also able to reduce the amount of required
unique tags but since all tag-combinations are introduced at the same step,
the sample handling and laboratory procedures are still relatively complex.
In addition, chimeric molecules may be formed in the library preparation
and since there should be different tags at the different ends of the reads,
these cannot not be detected and filtered away in the data analysis which
may result in reads originating from two different samples being erroneous
associated with a third sample.
Aim
If thousands of samples are to be tagged and prepared for sequencing it is
desirable that the procedure is as simple as possible so that human errors
can be avoided already at the design phase. The aim of this project was
to develop an easy scalable dual-tagging method for amplicon sequencing of
thousands of samples at a low cost.
Samples
To prove the concept of this method, the 270 bp long 2nd exon of the hy-
per variable gene DLA-DRB1 was amplified and sequenced for 4,700 samples
derived from dogs and wolves originating from all over the world. By com-
paring the allelic diversity of different geographical regions, the data can then
be used for confirming the geographical location of where the domestication
of the dog took place described previously [187, 188]. Of the 4,700 samples,
2,059 were collected by buccal swabbing and FTA-cards, 1,830 were blood
samples and 819 were hair samples.
Methods
The idea behind the method developed within this project is to use a two-
tagging strategy and a smart pooling procedure for reducing both number
of unique tags needed and sample handling complexity. This is achieved by
introducing the first barcode in the PCR step using 96 tagged PCR primer-
pairs, each of which is assigned to a specific well in the 8 x 12 grid that
constitutes a traditional 96-well PCR plate. Hence, they are named A1,
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A2, ..., H12 and denoted position tags. After amplification and tagging
of 96 samples, the PCR products are pooled. In order to avoid the time-
consuming step of determine the concentrations of all samples, the PCR is
cycled relatively many times to ensure that all samples reaches the ampli-
fication plateau and hence a somehow equal amount of end-product. This
should make the method robust enough for allowing pooling of equal volumes
using a multi-pipette rather than setting 96 different volumes per plate for
equimolar pooling using a single channel pipette.
All 96 samples from the plate have now become one single sample which
is purified from remaining primers and PCR reagents before the second tag,
specific for this plate and denoted plate tag, is introduced by ligation together
with the sequencing adapters. The whole procedure can then be repeated
until the desired amount of samples have been processed. In our case, 52
plates were made which gave a total of 4,992 uniquely tagged samples con-
suming only 96 + 52 = 148 unique tags. The number of desired tags t for a
certain sample size N can be calculated as
t =
N
96
+ 96
This procedure of tagging and pooling ensures a reliable and easy scalable
system since the most complex step, the position-tag PCR, is having the
same primer set-up for each plate and hence, a fool-proof procedure of trans-
ferring primer-pairs between a primer stock plate and the sample plate using
a multi pipette can be set-up. Once the PCR-step is carried out, the number
of samples to be handled is almost 100-fold decreased making the remaining
steps easy to handle.
In order to further decrease costs and hands-on time in this project, the
plate-tag and sequencing adaptor ligation was carried out using an auto-
mated protocol in a liquid handling robot [189]. To ensure an even read
distribution between the plates, the ligation products are quantified before
pooling them equimolar prior to emPCR and sequencing. The demand for
unique plate-tags in this particular experiment was further reduced by using
a three-region gasket in the sequencing run and hence, the plates were pooled
into three sequencing libraries.
3.2. PAPER II - SORTING GLOWING BEADS 57
Results and discussion
In order to estimate the success rate of the position-tag PCR’s, about half
of the samples were randomly picked and analyzed using agarose gel elec-
trophoresis or automated capillary gel electrophoresis. This resulted in a
success rate estimate of 79% and since samples were added to 4,708 wells
(248 wells were negative PCR controlls), the total number of PCR prod-
ucts was estimated to 3,700. After sequencing on a 454 GS FLX instrument
using the titanium chemistry generating 700,000 reads, a custom-made perl-
script was used for demultiplexing the reads. About 3,500 samples obtained
more than 20 reads which had been previously estimated to be sufficient for
confident genotyping [190]. This corresponds to 95% of the successful PCR-
products which means that almost all vital samples subjected to sequencing
were genotyped and this was (and still is?) the largest sample set to be se-
quenced within one machine run.
In conclusion, the method developed within this project is a good comple-
ment when the platform integrated indexing systems are insufficient. Even
thou several approaches for sequencing thousands of samples simultaneously
have been presented, none of these have actually captured the essence of the
problems that occurs when handling really large sample sets. These methods
have had the focus on reducing the quantity of unique tags required for a
specific sample size and in order to achieve this, sacrificed simplicity.
Since the throughput of today’s sequencing instruments is so large, there
are resources for targeting larger regions than just one single exon and still
investigating thousands of samples together. An adaption of the method
described here is presented chapter 3.3 where the double tagging system is
combined with hybridization capture and Illumina sequencing.
3.2 Paper II - sorting glowing beads
The idea of this project occurred during the development of the method
presented in paper I. After a pilot run on the 454-machine where a pool of 34
individuals was sequenced, an unexpected large proportion of the generated
sequencing data contained an unwanted byproduct, less than 100 bases of
length. Prior to sequencing, the by-product had appeared as a smear in the
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gel electrophoresis analysis but the sample had been purified by gel-cut prior
to emPCR and still, the by-product presence in the data was abundant. This
is where the idea of a method that would enrich the wanted molecules rather
than trying to get rid of the unwanted emerged. Since the PCR-tagging, 454-
sequencing and FACS-enriching of DNA carrying beads were already set-up
in the group, the idea could be tested relatively quick and the method proved
to be useful.
Background
Amplicon sequencing is an effective strategy for deep examination of small
genomic regions and the capacity of the next generation sequencing ma-
chines allows this to be done in a multitude of samples simultaneously which
even further increases the utility of the method. As mentioned in chap-
ter 2.1, PCR may generate unwanted side-products and primer-dimers. If
these molecules are not removed in amplicon sequencing experiments prior
to library preparation and emPCR, they will steal some of the sequencing
capacity. Additionally, if they are shorter than the main product, which is
common since they are more likely to occur if they are, they will be more
effectively amplified in the emPCR and thereby dominating the sequence
data. Applying size selection prior to library preparation is a common way
of removing by-products but this requires that the unwanted molecules are
of a sufficient different size to be discriminated from the main product and
even if the sample looks pure in a gel electrophoresis analysis, it may still
contain enough molecules for disturbing the sequencing experiment.
Aim
To make amplicon sequencing more effective, a strategy for enriching emPCR
beads carrying amplified target molecules using fluorescence activated cell
sorting (FACS) was developed.
Samples
The sample set consisted of a 34 individuals subset of the samples sequenced
in paper I. All samples were collected by buccal swabbing and FTA-cards.
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Methods
The emPCR beads were labeled using two different fluorophores: SYBR
Green, that binds all dsDNA and is used for discriminating between naked
beads and DNA carrying beads. The other fluorophore, Alexa647 is coupled
to a 50 bp synthetic oligo nucleotide complementary to the central part of
the amplicon so that it should not bind primer sequences but still be of suf-
ficient length to tolerate a few mismatches. Based on the fluorophore signal,
amplicon carrying beads can be FACS-enrichhed.
To evaluate the utility of enriching target carrying emPCR beads prior to
sequencing, three identical sequencing libraries were prepared from the same
amplicon pool of 34 individually dual-tagged samples. The amplification tar-
get was the same as in paper I: the 2nd exon of the hyper variable DLA-DRB1
gene. One library was attributed to traditional size-selection by gel-cut and
the other two were also target enriched using our new approach. All libraries
were sequenced in a 1/16 lane in a 454 GS FLX run.
Results and discussion
The data sets from the FACS-enriched sequencing libraries had a nearly
three-fold increase of quality reads compared to the traditionally purified
control library. The read length of the FACS-enriched libraries was also im-
proved compared to the control library where 69% and 75% of the reads
were longer than 200 bp compared to 41%. Since the amplification target
is situated within a hyper variable region, single nucleotide substitutions are
likely to occur within the probe binding region which also proved to be the
case among the 34 individuals included in the experiment. Mismatches in
DNA hybridization affects the binding strength so discrimination of individ-
uals non-identical to the DNA probe in the FACS-enrichment process lead-
ing to biased data might be a valid hypothesis worth further investigation.
Among the 34 samples, up to five mismatches were observed and to investi-
gate if this affected the enrichment efficiency, the reads for each sample was
counted within each library and compared between libraries. The largest
difference between sample read frequencies observed in the FACS-enriched
libraries compared to the control library was 3% but when analyzing the
occurrence of probe mismatches among samples with large differences, there
was no trend of samples with many mismatches being present in lower fre-
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quency in the FACS-enriched libraries. This suggests that the differences
observed are likely to be of stochastic nature.
In conclusion, this project resulted in a highly efficient method for minimiz-
ing the effect of unwanted by-products in amplicon sequencing experiments.
The strategy of using sequence specific fluorescently labeled probes for FACS-
enrichment was further investigated in the group and resulted in a method
for normalizing pooled MID-libraries [191]. Another utility of this approach
is to run a multiplex PCR followed by enrichment of several amplification
targets. However, the sequencing costs have declined since this project and
today it might be both easier and cheaper to just sequence deeper and filter
the by-product reads in the data analysis.
3.3 Paper III - the library
This project was initiated in October 2010 at the Department of Medical
Epidemiology and Biostatistics of Karolinska Institutet. At that time there
were few third-part library preparation kits on the market so sequencer users
had to rely on the expensive reagents provided by the sequencing platform
companies. There was also a lot of sample collection going on in the group
from tumor tissue and other limited sources and this is where the need for a
cheap, efficient and easy method for preparing sequencing libraries compati-
ble with the Illumina sequencing chemistry occurred.
Background
All of today’s sequencing platforms needs to incorporate universal sequencing
handles in the ends of the molecules to be sequenced to enable clonal am-
plification and sequencing using universal primers. This process, commonly
referred to as library preparation, is discussed in detail in chapter 2.4 but
briefly, it involves fragmentation, end-modification and adapter ligation fol-
lowed by enrichment of correctly ligated molecules by PCR. The effectiveness
of this process and the amount of starting material determines the quality
of the library and sequentially the quality of the generated data. Hence, if
the available amount of input material is limited, a highly effective process
is desirable.
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While the sequencing costs decreases, the proportional library preparation
cost within a sequencing experiment becomes larger which creates a desire
for finding cheaper alternatives than whats offered by the sequencing com-
panies. In targeted sequencing experiments, the capture reaction is the most
expensive step in the library preparation procedure so performing capture
on multiple tagged samples simultaneously has the potential of lowering the
total experiment cost significantly.
Aim
This project aimed to reduce costs, hands-on time and DNA consumption in
shotgun whole genome sequencing experiments as well as targeted sequencing
experiments. The strategy was to develop an effective, cheap and simple pro-
tocol for library preparation by eliminating as many cleanup steps as possible
and optimizing the reaction conditions so that the different enzymatic steps
are conducted in the same buffer by only varying the temperature. Multi-
plex target capture was also enabled by combining the library preparation
protocol and target capture by hybridization.
Samples
The DNA samples used in this study were obtained within an epidemiological
study called Cancer of the Prostate in Sweden (CAPS) which is a population-
based case-control study aimed to investigate genetic and dietary risk factors
associated with prostate cancer. Cases were identified from registers between
2001 and 2003. CAPS consists of a little more than 3,000 cases and 2,000
controls which have been included in several GWAS [192, 193] and hence,
SNP-chip data is available.
Methods
In the standard library preparation procedure provided by Illumina, three
column or bead based clean-up steps is required between fragmentation and
PCR enrichment. According to Qiagen, a manufacturer of column based
clean-up systems, the yield of one clean-up is 60-80% and sequentially, the
yield from three clean-up steps is 20-50%. In Illumina’s protocol, the adeny-
lation is carried out by the DNA polymerase Klenow exo− which catalyzes the
addition of a nucleotide to the 3’end of dsDNA fragments. Since this enzyme
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does not distinguish between different nucleotides, only 1/16 of the fragments
will be adenylated in both ends if all four nucleotides are present in the reac-
tion. Since they needs to be present in the end-repair reaction, a purification
step has to be included prior to adenylation to ensure its effectiveness. By
replacing Klenow exo− with an enzyme that specifically incorporates dATP’s
even thou all four nucleotides are present, this clean-up step can be avoided.
As it happens to be, the most widely used enzyme for PCR namely the Taq
DNA Polymerase exhibits this property. The name Taq is short for Ther-
mus aquaticus, which is the thermophilic bacteria the enzyme was isolated
from, discovered in the hot springs of the Yellowstone National Park [194].
Taq DNA polymerase has a very low activity at ambient temperatures and
needs to be heated to 72◦C in order to function optimal. This means that all
enzymes involved in end-repair, phosphorylations and adenylation (T4 DNA
polymerase, T4 PNK and Taq DNA polymerase respectively) can be added
to the same reaction and by altering the reaction temperature, the end-repair
and phosphorylation can take place at 25◦C and then the adenylation at 72◦C
whiles the two former enzymes are inactivated by the heat.
In Illumina’s library preparation protocol, the reaction buffer needs to be
exchanged and the adenylation enzyme removed prior to the ligation re-
action but by conducting all reactions in ligase buffer and since the former
enzymes are either heat inactivated or inactive at ambient temperatures, this
purification step can be skipped. After Y-adapter ligation however, excess
adapter constructs needs to be removed prior to enrichment by PCR or they
will form extensive amounts of primer-dimer by-products.
In the PCR enrichment step, sample specific barcodes are introduced en-
abling multiplex sequencing but also multiplex target capture for exome se-
quencing experiments. To enable multiplex capture of even greater multi-
tudes of samples using dual-tagging, the protocol can be modified by ligating
another barcode adapter prior to Y-adapter ligation. This allowed for cap-
turing a 500 kb region in 96 samples simultaneously.
For studying the outcome of different alterations in the library preparation
procedure, automated capillary electrophoresis and qPCR was used for as-
sess size distributions and amount of molecules available for amplification
using universal primers respectively. The library complexity was assessed by
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measuring the PCR-duplicate prevalence in the sequencing data using com-
putational tools like rmdup from the alignment manipulating utility collection
SAMtools [195] and MarkDuplicates from Picard [196].
Results and discussion
Several factors were varied for improving the efficiency of the procedure. A
lowered concentration of Taq DNA polymerase was tested since even though
its activity is low at ambient temperature it is still bound to the ends of the
DNA fragments and hence, hinders the DNA ligase from binding. Prolonged
ligation reaction duration and altered temperatures for phosphorylation and
end-repair was also tested. What showed to have an effect was the lowered
Taq concentration and the prolonged ligation duration.
Multiplex exome capture was carried out on 2, 4 and 8 samples simulta-
neously from 1 and 0.1 µg DNA and each capture library was sequenced on
1/8−1/6 lane on a Illumina HiSeq 2000 machine resulting in an overall mean
coverage of 42×. Since the same amount of bait molecules is used for several
samples in a multiplex capture, the number of molecules per sample becomes
less than in a single-pled capture. This might result in molecules not identical
to the reference allele used in the bait design becomes less prone to be cap-
tured because of competitive hybridization. To investigate if such bias was
introduced in the multiplex captures, the heterozygote variants called from
the exome data was compared to SNP-chip data resulting in a concordance
of 99.4% (requiring > 15× coverage). Neither degree of multiplicity nor in-
put DNA amount could be associated to level of concordance suggesting that
the underlying mechanism behind variation in captured allele frequencies is
of stochastic nature. Further investigations also showed that the multiplex
capture did not affect classical parameters used for measure the quality of
capture experiments such as GC-content bias, insert-size and fold base 80
penalty. The same comparisons were made for the 96-plex capture as well
with 99.8% concordance between heterozygote variant calls and SNP-chip
data (requiring > 15× coverage) and no observed effect on the other param-
eters.
In conclusion, this project demonstrated an improved efficiency and reduced
costs for preparing libraries suitable for both whole-genome and targeted
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sequencing experiments using next generation sequencing platforms. The
amount of DNA required for building a sequence library was reduced com-
pared to the manufacturer’s protocol but there are still other methods more
suitable for ultra-low DNA amounts such as Nextera (Illumina) [173] and
ThruPLEX (Rubicon Genomics). Still, the investigations of different factors
that affects efficiency and the multiplex capture procedure is useful informa-
tion for the sequencing community and several researchers who have read the
paper have contacted us requesting a detailed protocol.
3.4 Paper IV - DNA in circulation
This have been the main project for this thesis and is also the project where
most time have been spent during the last two and a half years. Initiated
in september 2010 when circulating tumor DNA had recently been shown
to be a promising biomarker in various forms of cancer [80, 81, 93, 94] it
was exciting working with something that could potentially change the way
cancer is handled. Several approaches for detecting circulating tumor DNA
have been tested on a multitude of samples generating tons of results of which
only a minor part ended up in the resulting manuscript. Hence, this is a good
place to present an extended edition of this project.
Background
There is no one questioning the utility of assessing cancer disease progression
and treatment outcome from a single (or a series of) blood sample(s). Using
free circulating tumor DNA (ctDNA) as a measure of the systemic tumor
load have been proposed and investigated by several studies [80, 81, 93, 94].
However, many of these have focused on patients with advanced disease and
a large tumor burden having a relatively large proportion tumor DNA. But
to be able to use ctDNA for early relapse detection, surgical outcome mea-
surement and early diagnosis, a robust detection of sub-1% levels of ctDNA
must be established. This has been achieved using various approaches such
as structural rearrangement breakpoint detection [93,94], sequencing tagged
amplicons of hot-spot mutations [197] and counting magnetic fluorescently
genotype specific labeled particles using flow cytometry [80,81,198].
However, the use of exome sequencing for detecting ctDNA have not yet
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been fully explored, even though it has been applied to monitor the genetic
evolution in response to therapy in metastatic cancers [199]. Since a vast
majority of all solid tumors harbors between 50-100 non-synonymous muta-
tions [40], exome sequencing of blood samples could be a universal tool to
assess these in a clinical setting. The challenges of applying this method is
the small amounts of available free circulating DNA and the low levels of
ctDNA.
Aim
This project aimed to investigate if it is possible to perform captured se-
quencing form small amounts of starting material, to assess the lower limit
of ctDNA detection, to benchmark this against a PCR-based method and to
investigate the presence of ctDNA in a small set of clinical samples.
Samples
The samples were selected from the STHLM2 study on the basis of the mu-
tation status of TP53 and recurrent disease. STHLM2 is a cohort study of
25,000 men with he aim of identifying and validate biomarkers of diagnostic
and prognostic value for prostate cancer. The collected material consists of
questionnaire data and blood samples. In total, three patients were selected
that had a mutated TP53, PSA relapse and late stage plasma and urine
samples available. Also, breast tumor tissue and blood samples was col-
lected from eight women who underwent surgery for primary breast cancer
at Stockholm South General Hospital (KARMAop-study).
Methods
Several approaches for ctDNA detection were investigated during this project.
Firstly, the use of structural rearrangement breakpoint detection using PCR-
based approaches was explored. To define the structural rearrangement
breakpoints within a tumor, low-pass whole-genome sequencing of tumor
tissue and germline DNA was applied. We focused on large deletions (>1kb)
and the computational approach for finding these is to identify pair-end reads
where the insert size is abnormally large. If the mean insert size is increased
in a sequencing experiment, a higher physical coverage of the genome will be
obtained at a given sequence coverage and hence, increasing the probability
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of identifying breakpoints. However, there are some restrictions of how long
fragments that can possible be sequenced using the Illumina platform. If the
fragments are too long, each cluster will occupy a larger area and hence, the
risk of overlapping clusters increases. This can be compensated by providing
less molecules to the cluster generation but consequently, this will decrease
the number of clusters and obtained reads. If the gain in physical coverage
comes with the cost of sequence depth, nothing is won so finding a balance
between longer libraries and conserved cluster density is of the essence.
Once some candidate deletions have been identified from the sequencing data,
these have to be validated before they can be used on precious plasma sam-
ples. This was done by running PCR over the breakpoint using tumor and
germline DNA and those breakpoints generating a product in the tumor
sample only was considered useful. To use these breakpoints for ctDNA de-
tection, some kind of method that quantifies their presence has to be applied.
We used a TaqMan PCR assay [200,201] combined with digital droplet PCR
(ddPCR). We applied this method on five breast cancer patients.
Since the process of developing and evaluate a specific assay for detecting
breakpoints for each tumor became very tedious, we also investigated the
use of exome sequencing for detecting tumor specific SNV’s. In a clinical
setting, it is preferable if the same experimental set-up can be used for all
patients which is achievable with a sequencing based approach and by tar-
geting a sufficient large part of the genome to ensure enough variation to
be captured within most tumors. There are two major challenges for this
approach: one is to generate enough sequencing library molecules to be sub-
jected to sequence capture from the relatively small amounts of DNA present
in a plasma sample. The second is to be able to detect tumor variants at
ultra-low frequencies and to distinguish them from sequencing error induced
background signals. To evaluate these limitations, we conducted exome se-
quencing experiments using various library preparation methods and input
DNA amounts. We then used the sequence data in silico to estimate the level
of background signals and compare them to the tumor signal from samples
of various tumor amount by statistical testing. Finally, we applied exome
sequencing on a set of clinical samples.
To benchmark the exome sequencing approach, we also amplified tumor spe-
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Figure 3.1 Results from the analysis of ctDNA in five breast
cancer patients (B-G) using ddPCR. A: proportion tumor allele
detected in DNA extracted from tumor tissue. B: tumor allele
in plasma collected just before surgery (P1). C: tumor allele in
plasma collected after surgery (P3).
cific SNV’s located in the gene TP53 and investigated the amplicons using
ultra-deep sequencing. This is a robust and easy method and to evaluate
the limit of detection, we constructed a synthetic ctDNA dilution series and
processed all dilution steps in five replicates. To investigate the impact of
template DNA length on the ability of detection, we mirrored the dilution
series using full length genomic DNA.
Results and discussion
TaqMan assays for detecting ctDNA was designed for five breast cancer pa-
tients and evaluated using conventional qPCR. Using ddPCR, ctDNA could
be detected in two out of five breast cancer patients (C and D) in blood
samples taken just before surgery (see figure 3.1). Out of the five patients,
these were the two that harbored the largest tumors. In sample D1P3, trace
amounts of ctDNA could be detected at a non-significant level. Since we
used a demonstration ddPCR-instrument, kindly provided by Bio-Rad, we
only had one day of use and therefore, we did not had the time to optimize
the PCR conditions for each assay. As seen in figure 3.1 A, the assays G1
and G2 did not work at all and there is great variance in the detected tumor
allele proportion using different assays within the same patient. This need
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Figure 3.2 Example of a allele discrimination plot from assay
D1 (N=normal, T=tumor, P=plasma, U=urine). On the y-axis is
the signal from the wild-type probe and on the x-axis is the signal
from the mutant probe.
of individual assay optimization makes this approach less suitable for clinical
implementation. Digital droplet PCR provided a high resolution analysis of
rare alleles and since two different fluorophores were used, one for the dele-
tion breakpoint and one for the wild type of the forward primer side of the
deletion, a two-dimensional map of the allele frequency for each droplet can
be constructed for each sample (see figure 3.2) However, there is a lot of
evaluation and optimization behind each assay which makes this method less
suitable in a clinical setting and further more, the cost of each assay is high.
Because of this, we decided to exclude this approach from the manuscript.
To evaluate the utility of captured sequencing from minute amounts of start-
ing material, we let two different library preparation methods, both of which
is dedicated to prepare sequencing libraries from small amounts of DNA, duel
against each other by performing sequence capture and sequencing from 1 ng
and 10 ng respectively. The outcome was the complexity of the capture li-
braries (the concept of library complexity is further discussed in chapter 2.4)
measured as the average sequence coverage after removing PCR duplicates.
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The two combatants were the ThruPLEX kit (Rubicon Genomics) and the
Mondrian system (NuGEN), both of which should be capable of generating
sequencing libraries from nano grams of DNA according to their respective
manufacturer. The average coverage using 1 ng and 10 ng of starting DNA
was 1.7× and 2.9× for the Mondrian system and 11.7× and 60.8× using
ThruPLEX. Thus, the superior winner was ThruPLEX which in addition,
had a very simple laboratory procedure.
The data generated in the comparison experiment was also used for deter-
mine the sensitivity of ctDNA detection using captured sequencing. This
was done by in silco estimation of background signal and generation of simu-
lated datasets of various tumor allele content. This resulted in an estimated
detection level of 0.5% with 95% sensitivity.
Sequencing an amplified tumor specific SNV for ctDNA detection was also
evaluated using a series of synthetic plasma DNA samples of various amount
of ctDNA. The different degrees of tumor allele content was processed in 5×
replicates and in the samples of lowest tumor allele content (aimed to be
0.025% and estimated to 0.03%), significant detection of tumor allele could
be achieved in 1 out of 3 replicates (the other two replicates experimentally
failed). The nature of PCR demands that the region to be amplified must
be continuously represented within a molecule to enable amplification and
hence, a fragmented sample must contain less molecules available for ampli-
fication than a non-fragmented sample. To test this hypothesis, a similar
series of tumor DNA diluted in germline DNA using non-fragmented sources
was made. The result from this was that the sample of lowest tumor content
had a mean estimate of 0.09% (again supposed to be 0.025%) and two out of
four replicates obtained significant detection. The estimate’s difference from
the estimate of the corresponding fragmented DNA sample might be from
pipetting errors as well as stochastic effects. No difference in the coefficient of
variance between replicates was observed either. Nevertheless, all replicates
of the second lowest tumor DNA content (supposed to be 0.05%) obtained
significant detection of tumor allele with mean estimates of 0.25% and 0.17%
for the non-fragmented and fragmented DNA respectively.
This PCR-based approach was applied on a series of clinical plasma and urine
samples from three prostate cancer patients taken at various time points. Sur-
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prisingly, they showed undetectable or very low levels of ctDNA even though
they were taken from patients having PSA relapse and a muted TP53 allele.
In the plasma taken from the patient having the highest PSA-value (114
ng/ml), 0.13% tumor allele was detected which stands in contrast to pre-
viously published work where patients with PSA levels between 17.4 ng/ml
and 808 ng/ml had ctDNA levels of 30-50% [202]. However, another study
has recently reported about severe colon cancer cases having undetectable or
very low ctDNA levels [203]. This suggests that there may be tumor phe-
notypes that are simply not so very prone to share their genetic material to
their surroundings and perhaps, these are more common within prostates?
Another explanation to the low ctDNA levels observed here might be that
the blood samples were not handled in an optimal way for ctDNA analysis.
Ideally, the blood should be spun and frozen within a few hours after it has
been taken but for some of the samples analyzed here, the needle-to-freezer
time was up to three days. During this time, blood cells might die and leak
DNA to the sample and also, nucleases may be active (in spite of the high
EDTA concentration) and degrading the free DNA. If these two processes
occurs simultaneously, the ctDNA will be heavily diluted in germline DNA
whiles the total concentration of free DNA remains somewhat unaffected.
We also applied exome sequencing to the same clinical samples but since
their ctDNA levels was below our in silico estimated level of detection, there
was no ctDNA detected.
To summarize, we showed that the ability of detecting low proportions of
ctDNA using exome sequencing is currently limited by the noise levels us-
ing Illumina sequencing. Nevertheless, we did show that exome sequencing
can be achieved from small amounts of starting material. Since information
about the mutational status of driver genes and genetic indications of therapy
resistance also is obtained, it might be of good use for monitoring treatment
outcome in severe cases having high ctDNA levels. The PCR-based methods
proved to be useful for detection of lower levels of ctDNA. Sequencing an
amplified SNV proved to be both simpler and cheaper than running ddPCR
over a breakpoint. It also indicated to have a lower limit of detection, even
though a fair comparison never was done. Sequencing amplified SNV’s is
attractive because of its ease of use and is also available for more labs, since
having a massive sequencer is more common than having a ddPCR machine.
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3.5 Future perspectives
The papers presented in this thesis have all enabled more efficient investi-
gations of DNA using sequencing. This is a filed that currently develops at
a very high pace and it is not far to conclude that technical achievements
rapidly becomes out of date. Nevertheless, the findings presented in this
thesis all aimed to make the most use of the massive throughput and en-
abling new applications rather than to improve it. The tagging procedure in
paper I will be even more applicable in the future since it not only enables
the analysis of thousands of samples simultaneously, but also facilitates a
logistic strategy to handle all these samples in the laboratory. This will be
of importance when even larger sample sets are to be processed.
The cost per sequenced base has decreased and will probably continue to
fall (maybe at a slightly lower pace) during the years to come which makes
the tolerance to data contamination and uneven read distributions across
samples larger. This might make the method of sorting DNA carrying beads,
presented in paper II, redundant but there is still some potential if larger sets
of targeted genes can be enriched from more complex sequencing libraries.
The library preparation and target enrichment procedure presented in pa-
per III has already been requested by several researches that have read the
article and perhaps the time when these findings are of most importance is
now? If the future holds library-free sequencing methods at extremely high
throughput, a method for preparing sequencing libraries and enriching ge-
nomic regions might not be essential.
The utilization of ctDNA for handling cancer is in its infancy and has not yet
been established in clinical practice. Currently, various methods are being
evaluated while trying to understand the biological mechanisms. The inves-
tigation of the limitations using exome sequencing for ctDNA applications
is therefore of great value. Knowledge of a weakness must be gained before
it can be turned into a strength and there is a high probability that assess-
ment of ctDNA using sequencing will be clinically implemented in the future.
During the last years, we have witnessed an explosion in sequencing tech-
nologies. Be aware, because the biological knowledge that follows is about
to burst.
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Populärvetenskaplig
sammanfattning
Alla celler innehåller en mängd olika proteiner som utför olika uppgifter,
till exempel energiproduktion, kommunikation, underhåll, transporter och
mekanisk hållfasthet. För att en cell skall kunna producera dessa proteiner
behöver den information om hur de skall sammansättas, en ritning. Denna
information finns lagrad i en molekyl som kallas DNA som är en lång kedja,
uppbyggd av fyra olika bitar som kallas baser (A, C, G och T). På samma sätt
som bokstäverna i den här texten bildar ord bestäms informationen lagrad
i DNA-molekylen av ordningen, eller sekvensen av baserna. Ritningen för
ett visst protein kallas gen och samlingen av alla ritningar hos en organism
kallas genom. Människans genom består av cirka tre miljarder (3×109) baser
som kodar för 20,687 gener och skulle man skriva ut alla dessa baser i en rad
med 1 mm breda bokstäver skulle den raden vara lika lång som resan från
Stockholm till Paris tur och retur (3,137 km). I denna skala skulle det finnas
en gen var 300:e meter och varje gen skulle vara i snitt 27 meter lång. När
man undersöker DNA brukar man vilja ta reda på i vilken ordning baserna
sitter i och denna process kallas för att sekvensera.
Cancer är en sjukdom som uppkommer för att baser ibland blir utbytta mot
andra baser, man säger att det sker en mutation. Detta kan hända på grund
av att cellens kopieringsmaskineri inte är helt perfekt när en cell kopierar hela
sitt genom inför en celldelning. En mutation kan vara både skadlig, gynnsam
eller inte alls påverka en cell och detta är en viktig mekanism som ligger
bakom det som kallas för evolution. En mutation kan också uppstå när en
cell utsätts för något i dess miljö som påverkar DNA-molekylen på ett skadligt
sätt, som till exempel ultraviolett strålning eller tobaksrök. En cancercell har
samlat på sig mutationer som gett den en överlevnadsfördel gentemot andra
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celler i dess närmiljö och kan därför växa snabbare och mer okontrollerat än
sina grannar. Som tur är tar detta väldigt lång tid och det är därför cancer
ofta uppkommer sent i livet.
I Sverige är prostatacancer den vanligaste formen av cancer hos män och
varje år får cirka 9,500 personer diagnosen, vilket motsvarar ungefär en tred-
jedel av alla manliga cancerfall. Prostatan är en körtel lika stor som en
valnöt som sitter under urinblåsan och omsluter urinröret. Det lömska med
prostatacancer är att sjukdomen är i princip symtomfri i tidigt skede och på
grund av prostatans lokalisering är det även svårt att upptäcka en tumör med
fingrarna. Prostatan utsöndrar ett protein som kallas PSA och genom att
mäta halten av detta protein i blodet kan man upptäcka om prostatan växer
vilket kan vara ett tecken på en tumör. För att utreda om en patient med ett
högt PSA-värde verkligen har prostatacancer tar man en biopsi för att un-
dersöka hur cellerna ser ut och utifrån denna kan en diagnos ställas. Genom
att titta på hur mycket cellerna har förändrats, hur stor tumören är samt
hur högt PSA-värde patienten har kan man avgöra om sjukdomen är aggres-
siv. För behandling av prostatacancer skiljer man på fall där hela tumören
växer inuti prostatan, så kallad lokaliserad sjukdom och fall där tumören
har spridits till omgivande vävnad eller andra organ, så kallad metastaserade
sjukdom. Lokaliserad prostatacancer kan behandlas med strålning, kirurgi
eller ibland inte alls beroende på patientens ålder, patientens allmäntillstånd
samt tumörens aggressivitet. Metastaserade prostatacancer behandlas oftast
med läkemedel som blockerar de hormoner som stimulerar tumören till att
växa.
I den här avhandlingen har en metod för att följa en tumörs utveckling med
hjälp av blodprover undersökts. Cellerna i en cancertumör är mer biokemiskt
aktiva än normala celler och en tumör utsöndrar därför också mer material
till sin omgivning än vad frisk vävnad gör. Bland annat utsöndras DNA och
eftersom en tumör bär på mutationer är detta DNA annorlunda i jämförelse
med resten av kroppens cellers DNA. Genom att sekvensera tumörvävnad
kan man ta reda på vilka baser som är muterade i en specifik tumör. Dessa
kan man sedan leta efter i det fritt cirkulerande DNA som finns i blodet och
på så sätt får man ett mått på hur stor och hur aktiv en tumör är. Det
svåra är att det även finns fritt cirkulerande DNA från friska celler i blodet
och halten av tumör-DNA är ibland väldigt låg (mindre än 1%). Det har
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vi löst genom att sekvensera de muterade positionerna väldigt noga för att
på så sätt få ihop tillräckligt många observationer för att statistikt kunna
säkerställa närvaro av tumör. Det som begränsar metoden är att den maskin
som utför själva sekvenseringen ibland gör fel så att det ser ut som om en
bas är muterad fastän den i själva verket inte är det. Det gäller alltså att
den muterade basen från tumören finnas närvarande i högre utsträckning än
sekvenseringsfelen för att kunna identifieras.
Den här metoden innebär att man kan följa hur en tumör svarar på olika
behandlingar. Man kan till exempel se att halten tumör-DNA sjunker när
patienten får cellgifter och att den stiger om en patient får ett återfall. Hos
en patient med hög halt tumör-DNA i blodet kan man även se om en tumör
får nya mutationer, som till exempel resistans mot en viss behandling. Ett
framtida alternativ till operation kan vara att ta fram en genetisk profil
för tumören utifrån en biopsi och sedan följ dess utveckling med hjälp av
cirkulerande tumör-DNA. Skulle man se att halten stiger och att tumören
fått gener associerade med aggressiv sjukdom muterade kan man besluta om
operation. På så sätt skulle många operationer som idag görs i onödan kunna
undvikas.
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